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ABSTRACT
OUTCOMES ASSOCIATED WITH THE UTILIZATION OF ANTIDEPRESSANTS
AND PSYCHOTHERAPY AMONGST CANCER PATIENTS WITH DEPRESSION
By Purva N. Parab, B. Pharm
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University
Virginia Commonwealth University, 2018
Advisor: Pramit A. Nadpara, Ph.D.
Assistant Professor, Department of Pharmacotherapy & Outcomes Science

Objective: To determine patterns of use, prescription medicine costs, office-based visit costs
and quality of life (QOL) across classes of antidepressants/psychotherapy in elderly cancer
patients. Methods: Medical Expenditure Panel Survey data files from 2005-2015 for cancer
patients with depression aged 18 years or older were used for the study. Frequencies of patients
under specific classes of antidepressants/psychotherapy were identified. Costs and QOL scores
were compared using Analysis of Variance (ANOVA). Generalized linear models,
linear/multinomial logistic regression were used for analyses adjusted for demographics, overall
health status, number and type of comorbidities. Results: The study sample consisted of 17,671
cancer patients with depression. 32.08% patients had an antidepressant prescribed whereas
15.30% reported psychotherapy. SSRI (62.44%) was the most frequently prescribed class. The
prescription and office-based visits costs were adjusted for demographics, overall health status,
number and type of comorbidities. These adjusted prescription costs were the highest for SNRI
(Mean = $112.92), adjusted office-based (psychotherapy) visit costs were the highest for those
receiving psychotherapy only without any antidepressant (Mean = $166.39/visit). QOL scores
were higher amongst patients who had combinations of antidepressants prescribed, specifically
SSRI with either a TCA or SNRI as compared to those who were prescribed an individual class
or those who did not receive any treatment at all. Conclusion: Antidepressants were prescribed
more often than psychotherapy amongst cancer patients with depression in the United States.
xii

The prescription costs and associated QOL scores were higher amongst those with
antidepressants prescribed as compared to those receiving psychotherapy with or without an
antidepressant for cancer patients with depression in the United States.

xiii

CHAPTER I: INTRODUCTION
Section 1.1: Background

Cancer is one of the most prevalent diseases in the country. In 2014, there were an estimated
14,738,719 people living with cancer of any site in the United States (US) and it was estimated
that there would be 1,688,780 new cancer cases in 2017.1 It has been listed as one of the priority
conditions by the Agency for Healthcare Research and Quality (AHRQ).2 The mean survival
rate of cancer patients was around 67% as per 2007-2013 data.1 Breast cancer is the most
common type of cancer with more than 255,000 new cases expected in the United States in
2017. The next most common types of cancers are lung and prostate cancer.1 Cancer patients
have a reduced quality of life (QOL). This could be due to treatment side effects, disability or
mental disturbance.3 There are also certain sociodemographic factors such as gender, marital
status, income or job status that affect the mental well-being and thus QOL of cancer patients.3
Patients who are over 65 years of age have an even more reduced QOL as compared to younger
patients.4
The AHRQ estimates that the direct medical costs for cancer in the US in 2014
were $87.7 billion. 58% of this cost was for hospital outpatient or doctor office visits whereas
27% of this cost was for inpatient hospital stays.5 Thus, it can be seen from these figures that
majority of cancer costs are associated with outpatient and physician office visits. Figure 1
below summarizes the major sources of payment for total annual costs of cancer patients for the
year 2014. As seen from the figure, the total share of out of pocket costs for all the cancer
patients in 2014 was $3.9 billion.5 On an average, cancer patients pay around $2116 to $8115
out of pocket annually. One in ten patients reported that the costs amounted to at least 63% of
their annual income.5 The financial burden on cancer survivors is thus high.6 The QOL of cancer
patients depends highly on the financial burden, mainly out of pocket costs of cancer patients
1

along with the cancer treatment provided.6,7 Cancer survivors with increased financial burden
have significantly lower physical and mental component scores and have higher odds of
reporting depressed mood.6 QOL and financial burden of cancer patients are thus correlated and
could depend on a lot of factors including the comorbidities involved.6,8
Other*
15%
Medicaid
4%
Out of Pocketa
4%

Private Insurance
44%

Medicare
33%

a-Total patient out of pocket costs per year = $3.9 billion
Other* - Employer’s Insurance, Tricare, Veteran’s Insurance and other state and local
government insurance
Figure 1: Sources of payment for total costs of cancer patients in the US per year 2014

Cancer and comorbidities:
Past literature suggests that, cancer has common risk factors with various other
conditions and hence has several comorbidities associated.8 Diabetes mellitus, chronic
infections, diseases of the immune system and psychosocial disorders are some of the commonly
identified comorbidities along with cancer.8 The impact of such comorbidities tends to be greater
for cancers with a better prognosis, since otherwise the patients are more likely to die from their
cancer regardless of other comorbidities associated.9 These comorbidities reduce survival and
lower QOL of cancer patients and hence it is necessary to study these and manage such
conditions effectively.9
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Depression as a comorbidity:
Diabetes, COPD/asthma and psychosocial stress are some of the commonly associated
comorbidities with cancer that further lead to a reduced QOL.8 The prevalence rates of
psychosocial stress in cancer patients ranged from around 23% to 53%.8 Untreated psychiatric
comorbidities in patients with cancer have a significant impact on disability, quality of life and
they tend to worsen if not treated adequately.10 Depression is one of the most commonly
associated comorbid psychiatric condition with any type of cancer. As compared to anxiety and
adjustment disorder, the prevalence of depression is 12% higher amongst cancer patients.11 In
addition, as compared to those without cancer, the prevalence of depression is higher in cancer
survivors.12 Clinicians working in cancer services have recognized that depression is often
undiagnosed and untreated and that these shortcomings in care can have substantial effects, not
only on patients' quality of life but also on their acceptance of cancer treatments.13 There is
evidence to support that pharmacological treatment mainly tricyclic antidepressants and
psychotherapy used to treat depression improve palliative care in cancer patients.14 There is also
evidence to support that the completion rate of cancer treatment is higher when the patient is
receiving some treatment for comorbid depression.15 Managing depression thus along with
improving QOL of patients also improves cancer treatment outcomes. Studies have
demonstrated that comorbid depression is also associated with an increase in total healthcare
expenditure by $6301 as compared to cancer patients without depression.16 On comparing
expenditures of cancer patients with depression and those without depression, the highest cost
difference was found in prescription drugs ($2,297 higher for those with depression) and other
expenses that included office-based and outpatient visits ($715 higher for those with
depression).16 The overall use of psychotropic drugs in palliative care of cancer has increased
from 2002 to 2009.17 Depression could be treated by either pharmacotherapy using different
types of antidepressants or by psychotherapy using methods such as counselling sessions,
3

certain social media interventions, etc. Studies have suggested that patients report higher interest
in counseling as compared to antidepressants however, the prevalence of antidepressants is still
higher than support groups or counseling for managing depression. 18,19 Since, the mechanism
of action and the side effects of these antidepressant classes differ from each other, it would be
hypothesized in our study that they would have varied effect on certain patient outcomes such
as quality of life.
Antidepressants:
There are various classes of antidepressants such as tricyclic antidepressants (TCAs),
selective serotonin reuptake inhibitors (SSRIs), serotonin- norepinephrine reuptake inhibitors
(SNRIs), monoamine oxidase inhibitors (MAOIs) and atypical antidepressants (miscellaneous
agents). Depression is a result of decreased levels of neurotransmitters like norepinephrine and
serotonin in the synapse. All the above-mentioned antidepressants act by increasing the amount
of such neurotransmitters. The mechanism of action of all these different classes of
antidepressants differ from each other. TCAs, SSRIs and SNRIs are reuptake inhibitors and they
block the reuptake of neurotransmitters, which increases their amount in the synapse. TCAs and
SNRIs increase serotonin and norepinephrine both whereas SSRIs only increase serotonin.
MAOIs act by decreasing the degradation of neurotransmitters in the synapse thus increasing
their amount. Monoamine oxidase is the enzyme responsible for breaking down the
neurotransmitters, which is blocked by the MAOIs.20 Miscellaneous agents also act by
enhancing the level of dopamine, serotonin or norepinephrine in the synapse. Figure 2 depicts
the different mechanism of actions of different classes. SSRIs are usually the most frequently
prescribed antidepressants in general population.21 If the trend is similar in cancer population
with depression is still ambiguous. The side effects that are associated with specific classes of
antidepressants differ. It has been mentioned in the literature that SSRIs are usually the most
tolerable.22 Table 1 summarizes the side effects and examples of each antidepressant class.
4

From a financial perspective, MAOIs are the most expensive with around $50-$80 out of pocket
for 30 tablets followed by SNRIs at $20 - $50, TCAs at $10 - $15 and the cheapest option is
SSRIs at $6 -$7 for 30 tablets.23 Looking at the prices, it is evident that the financial burden
arising across these classes would be varied. It is thus necessary to study the patterns of use
associated with individual classes of antidepressants and psychotherapy and to assess cost and
QOL outcomes associated with the same to manage depression efficiently. It would be
hypothesized in our study that the costs of cancer patients would differ significantly based on
the antidepressant that they have been prescribed.

Desipramine – TCA, Maprotiline, Trazodone – Miscellaneous Agents, Fluoxetine- SSRI
Figure 2: Summary of mechanism of action of all the antidepressant classes24
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Table 1: Side effects along with examples of each class of antidepressant
Antidepressant

Side effects

Examples

SSRI

Nausea, sleep disturbances, sexual dysfunction, appetite
changes, headache, dry mouth, slightly abnormal heart
rhythms

Fluoxetine,
Citalopram

SNRI

All of the side effects of SSRIs, hypertension, tachycardia

Duloxetine, Venlafaxine

TCA

Dry mouth, dizziness, blurred vision, constipation, sedation,
orthostatic hypotension, tachycardia

Amitriptyline,
Imipramine, Desipramine

MAOI*

All of the side effects of TCA, skin reaction, weight gain

Isocarboxazid,
Phenelzine, Selegiline

Miscellaneous
Drowsiness, hypercholesterolemia, weight gain
Agents
*Monoamine oxidase inhibitors
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Paroxetine,

Bupropion, Vilazodone,
Trazodone, Maprotiline

CHAPTER II: LITERATURE REVIEW
Section 2.1: Literature review
A literature review was conducted in order to assess the effects of antidepressants on
improving the quality of life of cancer patients and assessing the healthcare utilization
associated with it. The review was conducted using certain specific search terms. Based on the
literature and the background knowledge, we hypothesized that the effects of antidepressants on
QOL and the healthcare utilization associated with them would differ based on the different
classes of antidepressants and the results/findings would then help the patients and providers
manage depression more effectively.
Section 2.2: Systematic literature review on the effects of antidepressants on improving
the QOL of cancer patients and healthcare utilization associated with the same
A literature review was conducted in March 2017 using PubMed/Medline, CINAHL and
Google Scholar. The search term used was a combination of : (((("Antidepressive
Agents/economics" [Mesh] OR "Antidepressive Agents/organization and administration"
[Mesh] OR "Antidepressive Agents/therapeutic use" [Mesh])) AND ("Depression/drug therapy"
[Mesh] OR "Depression/economics" [Mesh] OR "Depression/epidemiology" [Mesh] OR
"Depression/prevention and control" [Mesh] OR "Depression/therapy" [Mesh])) AND
"Neoplasms" [Major]) AND Humans [Mesh] AND English [lang] AND cancer [sb] AND adult
[MeSH]. Titles and abstracts were screened. The following inclusion/exclusion criteria were
utilized:
Inclusion Criteria:
➢ Studies including outcomes related specifically to antidepressants.
➢ Studies published in English.
➢ Studies conducted on adult population over 18 years of age.
7

Exclusion Criteria:
➢ Not including any health outcomes.
➢ Not looking at depression as a comorbidity.
➢ Studies evaluating depression outcomes of the caregiver/spouse.
➢ Only psychosocial interventions.
The search criteria gave 372 articles. After removing duplicates, there were around 235 articles.
Applying the filters as per mentioned in the inclusion/exclusion criteria resulted into 71 articles.
These 71 articles were then screened by reading the titles and abstracts, out of which, 9 were
included in the final literature review.15,18,19, 25-30 These were most relevant to the study and
focused mainly on patient reported outcomes as opposed to just clinical outcomes. Figure 3
below depicts a flowchart of the article selection process.
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Total results through databases searching (n= 372)

Remove duplicates (n=137)

Articles screened for eligibility for studies published in
English and conducted on adult population (n=235)

Article excluded (n=164)

Titles and abstracts reviewed for eligibility (n=71)

Articles excluded (n=62):
• Antidepressants not the
primary focus (n=34)
• Narrative review/case reports
(n=15)
• Not the required outcomes
(n=5)
• Depression not a comorbidity
or depression of the
caregiver/spouse (n=5)
• Pediatric population (n=2)
• Only psychosocial
intervention (n=1)

Studies included (n= 9)

Figure 3: Article Selection Process
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A study was found looking at patterns of use and predictors of antidepressants,18 another
was found looking at the healthcare expenditures25 whereas all others were looking at
QOL.15,19,26-30 Most of the studies were clinical trials conducted on a small sample size and were
restricted to either one type of cancer or just one particular antidepressant intervention.
Therefore, our study would help in filling these gaps in the literature by looking at all types of
cancers and comparing all the classes of antidepressants in a nationally representative sample
thus increasing the generalizability.
Section 2.3: Literature summary
Most of the articles out of the 71, focused mainly on the clinical effects such as level of
neurotransmitters in the brain or other pathology resulting from the antidepressants rather than
focusing on the patient reported outcomes. In addition, many studies reported only the
prescribing trends of antidepressants in the population without cancer or did not focus on QOL
or healthcare utilization.
The nine studies that were selected were mainly those that reported QOL of cancer
patients or the depression scores for the same.15,19,26-30 These were mainly clinical trials looking
at the effects of one of the antidepressants on depression of cancer patients mainly including
specific types of cancers.15,26-28 Table 2 would summarize the studies finalized for the literature
review.
Patterns and predictors of antidepressant use:
A study conducted by Fisch et al. prospectively looked at patterns of use and predictors
of antidepressant use in ambulatory cancer patients with common solid tumors.18 It was
observed that, antidepressants were prescribed in 19% of all patients. The predictors identified
with the use of antidepressants were depressive symptoms, family history of depression,
concurrent medication use, cancer treatment status and certain other clinical and demographic
10

variables. However, the authors did not look at classes of antidepressants separately. In addition,
the study sample was restricted to ambulatory breast, prostate, colon/rectum or lung cancer
patients.
Healthcare Expenditures:
A study conducted by Alwhaibi et al. examined the association between depression
treatment and healthcare expenditures among elderly with depression and incident cancer using
Surveillance, Epidemiology and End Results (SEER) – Medicare.25 They suggested that, the
average 1-year total healthcare expenditures after depression diagnosis were $38,219 for those
not receiving any depression treatment, $42,090 for those receiving antidepressants, $46,913
for those who received psychotherapy only and $51,008 for those receiving both the therapies
(antidepressant and psychotherapy). Thus, the costs associated were the highest for those
receiving both the therapies followed by psychotherapy only. This study however looked only
at elderly population and restricted only to incident breast, colorectal or prostate cancer. In
addition, the authors did not look at classes of antidepressants separately.
Quality of Life (QOL):
There were studies conducted by Navari et al.,15 Fisch et al.,26 Holland et al.,27 and
Roscoe et al.28 which looked at effects of any one of the antidepressant namely paroxetine,
fluoxetine or desipramine on depression amongst cancer patients. The studies mentioned above
were prospective clinical trials focusing on one particular antidepressant rather than comparing
outcomes across different classes of antidepressants. A study conducted by Navari et al. looked
at the effects of fluoxetine on treating depressive symptoms in patients with early stage breast
cancer undergoing adjuvant therapy. It was found that 87% of the patients treated with
fluoxetine had a significantly higher completion rate of the adjuvant treatment as compared to
50% in the placebo group. The number of patients with a significant improvement in the QOL
11

was higher in the fluoxetine group as compared to those in the placebo group (79.6% vs 22.2%).
The subgroup of patients showing higher levels of depressive symptoms on the two-question
screening survey were the most likely to benefit from the treatment.15 In a study conducted by
Fisch et al., the effects of fluoxetine on QOL were studied. It was observed that, patients treated
with fluoxetine exhibited a significantly greater improvement in QOL as shown by the
Functional Assessment of Cancer Therapy–General (FACT-G) scores (improved by 8.82 points
from baseline to the fifth visit), compared with patients given placebo (improved by 5.64 points
from baseline to the fifth visit). The level of depressive symptoms expressed was lower in
patients treated with fluoxetine.26 It was observed that, when fluoxetine was compared to
desipramine by Holland et al., both were effective in treating depressive symptoms, with
fluoxetine being slightly better than desipramine in terms of efficacy and improving QOL (mean
change for Short Form Health Survey scores was higher with fluoxetine).27 Roscoe et al. studied
the effects of paroxetine on reducing depression amongst cancer patients. It was found that
paroxetine had an effect on decreasing depression, as observed from the reduced CES-D scores
(reduced from 14.7 to 8.8 across four cycles) and POMS-DD scores (reduced from 2.9 to 1.2
across four cycles) as compared to placebo group (CES-D scores reduced from 14.7 to only 12.6
and POMS-DD scores reduced from 3.2 to only 2.2 across four cycles). The decrease in
depression over time was significant for both the measures namely, CES-D and POMS-DD,
which indicate a positive effect of the antidepressant.28
A study conducted by Lloyd-Williams et al., looked at the longitudinal effect of
antidepressant medication in a cohort of advanced cancer patients. It was a prospective study,
where recruited patients were asked to fill baseline and follow-up questionnaires for assessment.
The questionnaires used were PHQ 9 (Patient Health Questionnaire) and EDS (Edinburgh
depression scale) tools for measuring depression. It was observed that 25% of patients were
taking some antidepressant medication at some point during the trial period. 77% patients were
12

prescribed SSRIs and none were prescribed TCAs. Patients taking some antidepressant reported
a significantly lower score on both EDS (3.18 point score reduction) and PHQ 9 (2.71 point
score reduction) as compared to those taking none indicating a lesser tendency towards
depression and hence a positive effect of the medication.29 However, in this case, the
antidepressants were not compared to psychotherapy.
There was another study conducted by Vyas et al., which was a population-level analysis
looking at the impact of depression treatment on health-related QOL among adults with cancer
and depression using Medical Expenditure Panel Survey (MEPS). It was observed that, adults
who reported psychotherapy with or without any antidepressant had higher Physical Component
Score (PCS) indicating a positive effect of the treatment (mean = 40.97), as compared to those
without any treatment (mean = 40.72) or with antidepressants only (mean = 39.87), this
difference was however not significant. Mental Component Scores (MCS) was the lowest for
those receiving psychotherapy with or without any antidepressant (mean = 39.23) as compared
to those without any treatment (mean = 43.78) or those with antidepressants only (mean =
44.37), this difference was significant. The study thus, suggested that QOL as measured by PCS
was numerically the highest for psychotherapy whereas that measured by MCS was the highest
for antidepressants only. However, this study did not look at classes of antidepressants
separately.30
Based on a study conducted by Wu et al., which was a survey-based prospective study,
51.4% women were extremely interested in individual counseling, 38.1% women were
interested in support group whereas antidepressant medications were rated the lowest. Interest
for each of the treatments was not related to demographic/disease factors. It was positively
related to self-rated health. Women with higher self-rated health reported more interest in
counseling than those with lower self-rated health.19
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Table 2: Literature Summary
Study

Fisch et al.
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Objective

To identify
determinants of
prescribing
antidepressants

Study Design

Sample

Patterns of use/ Predictors
Prospective
Ambulatory
observational
patients with
study
breast, prostate,
colon/rectum or
lung cancer

Conclusion

- Antidepressants -19%
Individual counseling 8.6%
Support group -8%
- Predictors:
Depressive symptoms,
family history of
depression, concurrent
medication use, cancer
treatment status, poor
quality of life and
demographic variables

Healthcare expenditures
Alwhaibi et al.25

To examine the
association
between depression
treatment and
healthcare
expenditures

Retrospective
longitudinal
study using
SEER* dataset

Elderly
Medicare
beneficiaries
with incident
breast, colorectal
or prostate
cancer

- The use of
combination of
antidepressant and
psychotherapy was
associated with the
highest total
expenditures followed
by psychotherapy only.

Quality of Life (QOL)
Navari et al.15

Fluoxetine v/s
Placebo in breast
cancer patients

Randomized
prospective trial

Newly
diagnosed early
stage breast
cancer patients

- Higher QOL and
completion rate of
cancer treatment with
the fluoxetine group

Fisch et al.26

To determine
whether fluoxetine
improves overall
quality of life
(QOL) in advanced
cancer patients
with symptoms of
depression revealed
by a simple survey.

Prospective
double blinded
trial to receive
either fluoxetine
or placebo for 12
weeks

Advanced
cancer patients
with an expected
survival between
3 and 24 months

- Fluoxetine exhibited
a higher significant
improvement in QOL as
compared to the placebo
group and decreased
depressive symptoms, as
indicated by the FACTG scores
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Holland et al.27

Fluoxetine v/s
desipramine in
depressed women
with advanced
cancer

Prospective
double-blinded
trial

Women with
advanced cancer

- Both effective, with
fluoxetine being slightly
better than desipramine
in terms of improving
efficacy and QOL

Roscoe et al.28

Paroxetine v/s
Placebo in breast
cancer patients

Prospective
double-blinded
trial

Female breast
cancer patients
receiving at least
four cycles of
chemotherapy

- Reduced depression
with paroxetine as
observed from the CESD and POMS-DD scores

Lloyd-Williams
et al.29

To observe the
longitudinal effect
of antidepressant
medications in a
cohort of advanced
cancer patients

Longitudinal
Patients with
observational
advanced cancer
prospective study

- Patients taking some
antidepressant reported
a lower EDS and PHQ
score compared to those
taking none indicating a
lesser tendency towards
depression

Vyas et al.30

To examine the
association
between depression
treatment and
HrQOL among US
adults with cancer
and depression

Retrospective
study using
Medical
Expenditure
Panel Survey

Cancer patients
above 18 years
of age

- PCS was the highest
for psychotherapy
whereas MCS was the
highest for
antidepressants

Wu et al.19

To investigate
treatment
preferences for
depression

Prospective
observational
study

Women with
breast cancer
arriving for a
surgical followup,
chemotherapy or
radiation therapy
appointment

- 45.2% reported higher
levels of interest in
counseling compared to
antidepressants
- Women with higher
self-rated health
reported more interest in
counseling

* Surveillance, Epidemiology and End Results
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Section 2.4: Gaps in literature
It is evident from the existing literature that antidepressants help in improving QOL and
outcomes, such as completion rate of the cancer treatment. However, none of the studies have
looked and compared all the different classes of antidepressants. Most of the studies have either
looked at just one of the antidepressant or just looked at one type of cancer. Moreover, most of
the studies conducted have been randomized controlled trials with a small sample size, which
limits generalizability of the study. It is thus unclear from the existing literature as to which
class of antidepressant would prove to have maximum benefits in improving QOL. In addition,
none of the studies have looked at healthcare utilization/ healthcare costs associated with the
classes of antidepressants and the sociodemographic factors associated with each. The study
conducted by Alwhaibi et al.25 looked at healthcare utilization associated with antidepressants
as a whole and did not look separately at individual classes. In addition, the authors did not look
specifically at prescription medicine costs or office-based visit costs, which would be more
specific to the depression therapy classes. Our study would thus help in addressing these
limitations of the existing literature.
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Section 2.5: Specific Aims
Aim 1: To determine the patterns of use of antidepressants amongst cancer patients in the
US with comorbid depression and characterize the utilization of antidepressants based on
sociodemographic characteristics
A: To determine the patterns of use and prescription trends across different classes of
antidepressants
B: To characterize the sociodemographic factors associated with the utilization of
antidepressants
Aim 2: To compare costs and healthcare utilization (office-based visits) of cancer patients
across different classes of antidepressants in the US
A: To compare the prescription medicines expenditures, overall costs and out of pocket
expenses of cancer patients with comorbid depression across different classes of
antidepressants
B: To compare office-based visits along with the expenses related to these across cancer
patients with comorbid depression classified based on the class of antidepressants
Aim 3: To compare quality of life (QOL) of cancer patients in the US with comorbid
depression across different classes of antidepressants and psychotherapy
A: To compare the physical and mental component score (PCS/MCS) across different
classes in order to assess quality of life of cancer patients with comorbid depression
B: To compare Patient Health Questionnaire – 2 (PHQ-2) scores and the frequency of
depression obtained from Short Form version 12 (SF-12) to assess quality of life of
cancer patients along with comorbid depression
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Section 2.6: Conceptual Framework
Conceptual framework for this research was based on the Andersen Behavioral Model.
The model parameters were guided by existing literature and studies conducted in the same area.
The model was as follows:
Predisposing Factors:
Demographics (Age,
Gender, Marital
Status) and Social
Structure (Education,
Race)

Enabling Factors:
Employment status,
income

Need Factors:
Overall health status,
cancer characteristics
(cancer type, remission
stage, number and type
of comorbidities)

Outcomes:
1. Patterns of use of antidepressants (specific aim 1)
2. Prescription and office-based visit costs associated
across classes of antidepressants (specific aim 2)
3. QOL across classes of antidepressants (specific
aim 3)

Certain predisposing and outcome variables for our study were identified based on
studies conducted by Fisch et al. and Wu et al., which looked at patterns of use and predictors
for the use of certain drugs.18,31 Outcome variables for specific aim 2 along with certain enabling
and need factors were identified based on past studies looking at the costs associated with a
particular class of medication or economic burden studies.31,32 The outcome variables for
specific aim 3 were identified using the past QOL studies that have been summarized.15,19,26-30
There has also been a study conducted by Üstündağ et al. looking at factors affecting QOL of
patients on chemotherapy which also provided the framework for selecting certain predisposing
and QOL outcome variables.3
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Section 2.7: Rationale
As stated above, depression has been proven to worsen the condition of cancer patients
and managing the same has shown positive effects not only on the QOL but also on the outcomes
associated with cancer treatment.15,19,26-28 Despite that, there have not been many studies
assessing and comparing the effects of different classes of antidepressants on patient outcomes.
In addition, many of these studies have restricted to one single type of cancer and none of them
have looked at the comparison of healthcare costs or healthcare utilization across classes of
antidepressants.15,19,26,28 There have been cost studies comparing the psychosocial approaches
(self-administered psycho-educational intervention, nursing, tele and home care more costly and
effective than the usual care with no such intervention) used in treating depression in cancer
population; however, those did not take into account the pharmacotherapies available.33,34 There
have been no studies comparing various classes of antidepressants used in the management of
depression and comparing these with psychotherapy. Studies have only suggested that the effect
on reducing depression is higher when pharmacotherapy is used along with psychosocial
interventions and it has been assumed that pharmacotherapy would have greater effect than
psychosocial interventions.35 These have however been narrative reviews and no formal study
has been conducted yet comparing classes of antidepressants along with psychotherapy. This
study would thus help in providing evidence for the association between antidepressants and
QOL along with the costs associated across classes of antidepressants/ psychotherapy.
Furthermore, most of the studies conducted were either meta-analysis/narrative
reviews36,37 or randomized controlled trials (RCTs)15,26,27,28 which limit generalizability of the
study. Hence, there is a need to conduct a population-based study, which would look at effects
of different interventions and compare those, and which would help the patients and the
healthcare providers manage depression better. This study would thus be a nationally
representative population-based study using Medical Expenditure Panel Survey (MEPS)
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looking at different classes of antidepressants along with psychotherapy and analyzing which
of the intervention is the most effective in improving the quality of life (QOL) and the healthcare
utilization/costs associated with each. Sociodemographic characteristics and the general
patterns of use of antidepressants would also be studied. Such study is important for
understanding the subgroup differences in depression treatment patterns, in order to promote a
more effective management of depression amongst cancer patients. In addition, studying costs
and quality of life associated with each class of antidepressant would help in understanding the
economic burden on cancer patients and the value associated with each. Existing literature
suggests that the economic burden on cancer patients other than the costs incurred from the
cancer treatment are mainly because of office-based visit costs and prescription medicine
costs.16,32 These costs and QOL outcomes along with patterns of use would be explored in our
study across the classes of antidepressants and psychotherapy.
Based on the already existing literature, this would be the first population-based study
that would compare the different classes of antidepressants along with just psychotherapy and
would also include all types of cancer and not restrict to just one. This study would provide
certain guidelines to the provider, encouraging/ discouraging prescription of any particular class
of antidepressant or psychotherapy and providing evidence to make certain decisions so as to
choose the depression therapy effectively. QOL outcomes would help clinicians in making a
better-informed decision regarding prescription of any therapy. In addition, it would also help
policy makers in guiding their decision for coverage of any particular antidepressant or
encouraging coverage of specific psychotherapies in a specific population.
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CHAPTER III: SPECIFIC AIM I
Aim 1: To determine the patterns of use of antidepressants amongst cancer patients in the
US with comorbid depression and characterize the utilization of antidepressants based on
sociodemographic characteristics
A: To determine the patterns of use and prescription trends across different classes of
antidepressants
B: To characterize the sociodemographic factors associated with the utilization of
antidepressants
Section 3.1: Methods
Design:
A cross-sectional, retrospective study design was implemented for all the specific aims
Data:
A nationally representative publicly available dataset called Medical Expenditure Panel
Survey (MEPS) was used for the study. MEPS, which began in 1996, is a set of large-scale
surveys of families and individuals, their medical providers (doctors, hospitals, pharmacies,
etc.), and employers across the United States conducted by the Agency for Healthcare Research
and Quality (AHRQ). The MEPS household component files provide data on demographics of
the participants, population characteristics, medical conditions, prescribed medicines, data on
inpatient and outpatient/office-based visits and all the expenses made by the patient including
out of pocket and any type of insurance coverage offered. The full year consolidated file of the
household component also contains information on the quality of life and the physical/mental
wellbeing of the patient, which was used for the study. Data from January 2005 to December
2015 data files was used for this study. Full year consolidated files were used to identify patient
demographics, medical conditions files were used to identify patients, prescription medicines
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files were used to identify the use of antidepressants, and office-based medical provider visits
files were used to identify psychotherapy visits for depression.
Study sample:
The medical conditions file of the household component provides the International
Classification of Diseases (ICD-9) codes for patient diagnoses. These codes were used to
identify patients. Clinical Classification Software (CCS) collapses categories based on ICD-9
codes and generate more meaningful codes which can be used to look at broader categories like
‘cancer’ and not a specific type of cancer. Hence, clinical classification codes of 11-44 were
used to identify cancer patients.38 There were around 204,732 people who responded to MEPS
from 2005 to 2015. The study sample was then restricted to adult respondents who were
diagnosed with or had cancer after the age of 18 years (n = 60,237), as identified by the CCS.
Adults who died during the process of reporting were excluded and hence the study sample
consisted of cancer survivors. The sample was then restricted to 21,413 patients who also had
an ICD code of 296 or 311 or a clinical classification code of 657, indicating depression
condition. These 21,413 patients thus had cancer along with depression. Patients who also had
an ICD code for bipolar disorder or schizophrenia (n = 3,742) were further excluded, since, in
these cases antidepressants are used for non-depression conditions. The final study sample, thus
include 17,671 cancer patients along with comorbid depression, diagnosed after the age of 18
years in the US. Figure 4 depicts the final sample size.
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MEPS 2005-2015 Population
(N= 204,732)

Cancer patients ≥ 18 years of age
(N=60,237)

Cancer patients with comorbid
depression (N=21,413)

Excluded those with bipolar
disorder and schizophrenia
(N=3,742)
Cancer patients ONLY with
comorbid depression (N=17,671)*
*These were the cases identified in the US with cancer and depression diagnoses and
formed the final sample size
Figure 4: Sample size flow chart for all the study aims
Variables:
Therapeutic drug class variables:
Prescription Medicines files from 2005-2015 were used to identify the antidepressants,
if any, prescribed to a patient. MEPS classifies drugs based on their therapeutic class under
‘Multum Therapeutic Class’. A specific code is given to one class of drugs under these Multum
classes. These codes were used to capture the drug use. Following Table 3 summarizes the codes
used.
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Table 3: Codes used to identify antidepressant classes using MEPS Prescription Files
Multum class

Code

Antidepressant class

TC1S1

208

SSRI

TC1S1

209

TCA

TC1S1

308

SNRI

TC2S1

250

MAOI

TC2S1

76

Miscellaneous*

TC1S1

307, 306

Miscellaneous (including
Tetracyclic, Phenyl
piperazine)**

* Separately coded as miscellaneous antidepressant agents by MEPS
** Considered these categories as miscellaneous for this study’s purposes

Based on the codes mentioned above, a new categorical variable was created indicating
the classes of antidepressants (one specific or in combination) that were prescribed to a patient.
This variable also had two more categories. One was for identifying patients who did not have
any antidepressant prescribed but had psychotherapy or counseling session in order to manage
depression and another identifying those who used antidepressants and psychotherapy both
prescribed. Psychotherapy or counseling sessions were identified using office-based medical
provider visits files. These files capture psychotherapy by asking questions like: ‘Type of
Medical person the patient talked to on the visit’ (10 = Psychologist) and ‘Best category for care
the patient received on visit’ (4 = Psychotherapy/Mental Health Counseling). In addition,
modified CCS code of 657 captured under office-based procedural codes was also used to
identify these visits. The final categorical variable for the treatment of depression thus had six
categories, namely: SSRI, TCA, SNRI, Miscellaneous (tetracyclic and phenyl piperazine agents,
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other unclassified antidepressants), Psychotherapy only and both (Antidepressant and
Psychotherapy). MAOIs were removed from the classification since, they were not prescribed
anymore for depression amongst cancer patients and the sample size in that particular class was
found to be null. The combinations of antidepressants prescribed were identified using the round
number and the panel number that the medicine was obtained in, each unique round consisting
of approximately 3 months. The patients were considered to be using combinations of
antidepressants, if they had the same round number for any two classes of antidepressants. The
names of antidepressants under each class included by MEPS are summarized in Appendix
Table 1.
Prescription drug characteristics and patterns of use variables:
Prescription medicines files were used to obtain drug characteristics. Variables such as
the quantity of prescribed medicines and days supplied of prescribed medicine were used as
prescription drug characteristics. Antidepressants were considered to be given in combinations
if the round number that the patient reported for these was the same. It is possible that within 3
months of a specific round a patient was switched to another class, this would however be
captured as a combination in our study. Combinations of antidepressants with psychotherapy
were identified too. The trends in the use of different classes of antidepressants from 2005-2015
was identified using the drug codes specific to a particular year, which was obtained from the
Panel Round number captured in the full year consolidated files. The patterns of use were further
described using sociodemographic variables.
Cancer characteristics and comorbidities:
Type of cancer was identified using full year consolidated files. Cervical, breast, colon
and lung were the major types of cancer identified and prostate, melanoma, liver, kidney and
pancreatic cancer were clubbed under one “other/non-specified” category along with some non25

specified cancers. Arthritis, asthma, diabetes and high blood pressure were identified as major
comorbidities associated with cancer patients along with depression based on the past
literature.8,30,39 The number of comorbidities (combinations of those mentioned above) were
identified across classes of antidepressants/psychotherapy.
Sociodemographic variables:
Full Year Consolidated files were used to obtain sociodemographic characteristics of
patients and compare them across different classes of antidepressants. The variables included
were sex, race, age, marital status, income, education and employment status. Sex, race and
marital status were used directly from MEPS whereas age, income, education and employment
status were recoded into meaningful categories. Age was a continuous variable and it was
recoded into 3 categories: “18-44 years”, “45-65 years” and “>65 years”. Income was also a
continuous variable which was collapsed into 3 categories: “low” (< $12,060), “middle class”
($12,060 - $48,240) and “high” (> $48,240). These income ranges for these categories were
identified based on the federal poverty line (FPL). The FPL for 2018 was $12,060 annual
income which was considered 100%, hence below this limit was identified as low income,
between 100-400% ($12,060 - $48,240) of FPL was identified as middle class income and over
400% FPL (>$48,240) was identified as high income. These ranges were identified based on
another study looking at drug expenses and the FPL guidelines.31,40 Education was recoded to 5
categories: “0: No education” (Kindergarten only and no years of schooling), “1: Elementary
(Elem)/ Middle (Mid) School” – grades 1-8, “2: High school” (grades 9-12), “3: ≤ 4 years of
college” (≤ 4 years of college after the 12th grade) and “4: 5+ Years College”. Employment was
recoded to form two broader categories, namely: “Employed” and “Unemployed”.
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Statistical Analyses:
Patterns of use of antidepressants and the combinations used were assessed using
number of prescriptions that were obtained from the Prescription Medicines Files using the drug
codes. Event-level files were summarized to patient-level files using PROC MEANS and PROC
TRANSPOSE procedures in SAS. ANOVA procedure was used to compare means of quantity
and days across different classes of antidepressants. Chi square tests were used to compare and
assess the significance of sociodemographic characteristics across different classes of
antidepressants and based on these results, characteristics were included in a multinomial
logistic model predicting the likelihood of receiving any particular class of antidepressant. The
preliminary chi square tests (PROC SURVEYFREQ) were significant for all the
sociodemographic factors such as sex, age, income, race, marital status, employment status and
education, hence, all of these were included in the regression model. Multinomial logistic
regression approach (PROC SURVEYLOGISTIC) was then used to calculate odds ratios (OR)
and estimate the likelihood of receiving any particular antidepressant and hence define the
patterns of use and predictors of receiving the treatment further. The model used for multinomial
logistic regression was as follows:
Logit (y=a*) = log p(y=a*) = β0 + β1 . Age + β2 . Gender + β3 . Race+ β4 . Marital Status +
1-p(y=a*)
β5 . Education + β6 . Employment Status + β7 . Income + Ɛa
*-Either SSRI, Miscellaneous agents, SNRI, TCA, Psychotherapy (Reference = No
antidepressant/psychotherapy), a-Error Term

Trends in the utilization of antidepressants across the study period of 2005 to 2015 were
compared by plotting graphs for each class of antidepressant/ psychotherapy. For trends, the
percentages, calculated using the following formula, were plotted for each year:
Number of those who were prescribed xa in one particular year
100
Total number of antidepressant/psychotherapy prescription in that particular year
a – SSRI/Miscellaneous Agents/SNRI/TCA/Psychotherapy
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Trends throughout the study period were compared for each individual class by
conducting Cochran-Armitage trend test for categorical data. After running the analyses, the
data was summarized using means and frequencies for continuous and categorical variables
respectively and OR for logistic regression results. All the analyses was weighted by using
pooled weights from all the years. All the analyses were conducted using 0.05 as the significance
level. The hypothesis tested in this analysis was that the patterns of use and the trends of
antidepressants would differ significantly across the groups. In addition, the sociodemographic
characteristics would also differ and would be significantly associated with the likelihood of
receiving any specific class of antidepressant/ psychotherapy. SAS v9.4 and MS Excel 2016
were used for the analyses and for plotting graphs.
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Section 3.2: Results
Aim 1A: To determine the patterns of use and prescription trends across different classes
of antidepressants
Total sample size for the study consisted of 17,671 (weighted frequency = 16,478,908)
cancer patients with depression. Out of this, 32.08% (n = 5,669) had some antidepressant
prescribed to them either in combination or of one particular class. 15.30% (n = 2,705) reported
psychotherapy or mental counseling for managing their depression. There were around 7.25%
patients (n = 1,282) who reported the use of both that is pharmacotherapy (antidepressant) and
psychotherapy both at a time. There were around 53.64% patients (n = 9480) with no treatment
for depression and hence were untreated. Hence, patients either had untreated depression or
were prescribed an antidepressant, psychotherapy or a combination of both for managing their
depression. Amongst those who were prescribed antidepressants, 62.44% patients (n = 3,540)
were on SSRI, whereas 20.19% (n = 1145) were on miscellaneous agents that also included
1.09% tetracyclic (n = 62) and 3.2% phenyl piperazine (n = 187) agents in addition to those
defined as miscellaneous by MEPS, around 13.31% (n = 755) were on SNRI. 4.03% (n= 229)
patients were on TCA. The sample sizes of patients per antidepressant class along with their
weighted frequencies are summarized in Table 4.
Table 4: Sample sizes (unweighted and weighted) per antidepressant class
Antidepressant

Frequency

Weighted
Unweighted
Frequency
Percent
SSRI
3,540
3,545,671
62.44
Miscellaneous Agents
1,145
1,182,517
20.19
SNRI
755
803,590
13.31
TCA
229
199,423
4.03
Total
5,669
5,531,052
100
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
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Amongst those who were prescribed antidepressants, around 5.6% patients (n=318)
reported using combinations of different classes. Out of these 318 patients who were using
combination therapy, most of them (56.28%, n = 179) were prescribed a combination of SSRI
and one of the miscellaneous agents (usually Bupropion). Some other combinations identified
were, SSRI - TCA, SSRI - SNRI and SNRI – miscellaneous agent. There were very few who
were prescribed some other combinations such as, TCA with either SNRI or a miscellaneous
agent. SSRI and miscellaneous agents were the most frequently prescribed classes individually
or in combination. The frequencies of patients receiving a combination therapy are summarized
in Table 5 along with their weighted frequencies per combination.
Table 5: Frequencies for combinations of antidepressants
Combination of
antidepressants

Frequency

Weighted
Frequency

Unweighted
Percent

SSRI – MA*
SNRI – MA*
SSRI – SNRI
SSRI – TCA
Other combinationsa
Total

179
47
42
34
16
318

193,074
53,902
44,889
27,236
20,432
343,002

56.28
14.77
13.20
10.69
5.03
100

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
a
Other combinations include TCA either with a miscellaneous agent or SNRI

As mentioned above, some antidepressants were also used in combination with
psychotherapy (n = 1282). SSRI was the most commonly prescribed class along with
psychotherapy (n = 733, 57.17%). TCA (n = 29, 2.26%) was a rarely prescribed class in
combination with psychotherapy. These combinations are summarized in Table 6 using
weighted and unweighted frequencies.
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Table 6: Frequencies for combinations of antidepressants along with psychotherapy
Antidepressant with
psychotherapy

Frequency

Weighted
Frequency

Percent

SSRI
733
802,998
57.17
Miscellaneous agents
338
392,011
26.36
SNRI
182
122,321
14.19
TCA
29
25,242
2.26
Total
1,282
1,282,751
100
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants

All the above findings suggest that SSRI and miscellaneous agents were the most
frequently prescribed antidepressants to manage depression amongst cancer patients. These
were also the classes of antidepressants used most frequently in combination with one another
or with psychotherapy.
Cancer characteristics including the type of cancer, the remission state and other
comorbidities associated with cancer patients are summarized below in Table 7. Cancer type
and remission state had more than 90% missing values and hence were excluded from further
analyses, since they did not have any effect on the outcome variables. Number and type of
comorbidities had fewer missing values and hence were included in the analyses further.
Table 7: Cancer Characteristics across classes of antidepressants and psychotherapy
Cancer
characteristic
Cancer Type
Cervical
Breast
Colon
Lung
Other/Non-specified
Missing
Remission State
Yes
No
Missing

SSRI
(N=3540)

Antidepressants
MA*
SNRI
(N=1145)
(N=755)

TCA
(N=229)

Psychotherapy
(N=2705)

37 (1.04)
46 (1.29)
11 (0.31)
6 (0.16)
64 (1.80)
3,376 (95.36)

8 (0.69)
17 (1.48)
6 (0.52)
5 (0.43)
23 (2.00)
1,086 (94.84)

9 (1.19)
17 (2.25)
2 (0.26)
3 (0.39)
15 (1.98)
709 (93.90)

1 (0.43)
2 (0.87)
2 (0.87)
1 (0.43)
3 (1.31)
220 (96.09)

19 (0.70)
31 (1.14)
9 (0.33)
1 (0.03)
33 (1.21)
2,612 (96.56)

75 (2.11)
6 (0.16)
3459 (97.71)

25 (2.18)
23 (3.05)
1 (0.08)
0 (0.0)
1,119 (97.72) 732 (96.95)

4 (1.75)
0 (0.0)
225 (98.25)

30 (1.10)
1 (0.03)
2674 (98.85)
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Comorbidities
Diabetes
311 (8.78)
112 (9.78)
88 (11.65)
26 (11.35)
Arthritis
1,029 (29.06) 393 (34.32)
290 (38.41) 90 (39.30)
Asthma
413 (11.66)
158 (13.79)
96 (12.71)
31 (13.53)
High blood pressure
1,068 (30.16) 402 (35.10)
272 (36.02) 80 (34.93)
Missing
719 (20.31)
80 (6.98)
9 (1.19)
2 (0.87)
Number of
comorbidities
2
2,790 (78.81) 1,045 (91.26) 734 (97.22) 219 (95.19)
≥3
31 (0.87)
20 (1.74)
12 (1.59)
9 (3.94)
Missing
719 (20.31)
80 (6.98)
9 (1.19)
2 (0.87)
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents

351 (12.97)
659 (24.36)
513 (18.96)
696 (25.73)
486 (17.96)

2,175 (80.41)
44 (1.63)
486 (17.96)

Thus, as seen from the table above, the findings regarding the type of cancer and the
remission state across classes of antidepressants/ psychotherapy were inconclusive, since
majority of values were missing. With respect to comorbidities, arthritis and high blood pressure
were the most commonly associated conditions across all the groups. Almost the entire
population had at least 2 of these comorbidities. Some even reported having 3 or all of these
conditions.
Quantity of prescribed drugs and days supplied per prescription were then compared
across different classes to further explore patterns of use. It was found that the quantity of drugs
prescribed were the highest for miscellaneous agents (mean = 56.57), however the differences
within classes were not statistically significant (p-value > 0.05 for all comparisons). Days
supplied of prescribed medicine were the highest for SSRI (mean = 26.27), these were
significantly higher than that for TCA (p-value = 0.0357), however the other differences were
not statistically significant (p-value > 0.05). The means for quantity and days supplied of
prescribed drug are summarized below in Figure 5.
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Q U A N T IT Y O F D R U G S
P R E S C R IB E D ( M E A N )

49.9

53.2

53.6

D A Y S S U P P L IE D O F
P R E S C R IB E D M E D IC IN E
(MEAN)

56.5
26.27

23.72

21.61

16.53

SSRI

TCA

SNRI

SSRI

MA*

TCA

SNRI

MA*

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* – Miscellaneous Agents
Figure 5: Mean quantity and days supplied of medicine per fill across antidepressant
classes for cancer patients with depression in the US for the years 2005-2015

Since the differences were not statistically significant, it can be concluded that the
patterns of use with respect to the quantity and days supplied are similar across different classes
of antidepressants.
In addition, antidepressant and psychotherapy use was tracked across the study period
to identify the trends. Figure 6 depicts the trends per class. The observed trends remain
consistent with the findings above where SSRI is the most frequently prescribed class of
antidepressant followed by miscellaneous agents.
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Trends in Antidepressant and Psychotherapy Use
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* – Miscellaneous Agents
Trends reported are percentages observed per year out of all the antidepressants/
psychotherapy prescribed in that particular year
Figure 6: Trends in the use of antidepressants and psychotherapy throughout the study
period

As seen from the graph, the use of TCA from 2005-2015 has been minimum and has
been steady. The use of psychotherapy has increased until 2010 and has been stable ever since.
In the year 2008, there was a spike increase in the use of SNRI, however, the use decreased in
2009 and has again increased slightly in 2013 and remained stable ever since. The use of SSRI
has been more than 50% of all the antidepressants throughout the study period. The year 2009
witnessed an increase in the use of SSRI over 60%, however it decreased by 2010 and has been
stable ever since. Out of all of these, a significant change in trend (upward or downward) was
observed only for SNRI (p-value=0.0385 for a two-sided test), others were all non-significant.
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Aim 1B: To characterize the sociodemographic factors associated with the utilization of
antidepressants
Sociodemographic characteristics included in our study, age, gender, race, marital status,
education employment status and income were compared across the classes of antidepressants
and psychotherapy. The distribution of people per antidepressant/ psychotherapy class by the
sociodemographic factors mentioned above are summarized in Table 8.
Table 8: Sociodemographic characteristics of patients receiving antidepressant/psychotherapy
Sociodemographic
Factor

SSRI
(N=3540)

Antidepressants
MA*
SNRI
(N=1145)
(N=755)

TCA
(N=229)

Psychotherapy
(N=2705)

Age, years (range)
Mean

48.13

47.54

49.03

50.55

43.23

Age groups
18-44 years
45-65 years
>65 years
Missing

1,381 (39.01)
1,325 (37.42)
446 (12.60)
388 (10.96)

350 (30.57)
401 (35.02)
157 (13.71)
237 (20.70)

247 (32.72)
333 (44.11)
78 (10.33)
97 (12.85)

57 (24.89)
99 (43.23)
26 (11.35)
47 (20.52)

1,333 (49.29)
897 (33.16)
128 (4.73)
346 (12.81)

Male
Female
Missing

1,063 (30.03)
2,341 (66.13)
136 (3.84)

319 (27.86)
545 (47.60)
281 (24.54)

186 (24.64)
487 (64.50)
82 (10.86)

55 (24.02)
134 (58.52)
40 (17.47)

976 (36.08)
1,633 (60.36)
96 (3.54)

Whites
Blacks
Asians
Multiple Races
Missing

1,943 (54.89)
668 (18.87)
534 (15.08)
300 (8.47)
95 (2.68)

752 (65.68)
146 (12.75)
34 (2.97)
67 (5.85)
146 (12.75)

620 (82.12)
39 (5.17)
7 (0.93)
17 (2.25)
72 (9.54)

85 (37.12)
114 (49.78)
3 (1.31)
3 (1.31)
24 (10.48)

2,296 (84. 87)
216 (7.98)
37 (0.93)
84 (3.10)
72 (2.66)

Married 1,478 (41.75)
Widowed
254 (7.18)
Divorced
552 (15.59)
Separated
126 (3.56)
Never Married
871 (24.60)
Missing
259 (7.32)
Education
No education
10 (0.28)
Elem/Mid School
229 (6.47)

323 (28.21)
58 (5.07)
289 (25.24)
42 (3.67)
223 (19.48)
210 (18.34)

322 (42.65)
51 (6.75)
146 (19.34)
24 (3.18)
127 (16.82)
85 (11.26)

79 (34.50)
20 (8.73)
34 (14.85)
4 (1.75)
48 (20.96)
44 (19.21)

681 (25.17)
96 (3.54)
494 (18.26)
115 (4.25)
962 (35.56)
355 (13.19)

14 (1.22)
156 (13.62)

7 (0.93)
38 (5.03)

0 (0.00)
23 (10.04)

108 (4.36)
477 (17.64)

Gender

Race

Marital Status
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High School
≤ 4 Years College
5+ Years College
Missing

1,037 (29.29)
872 (24.63)
204 (5.76)
1,188 (33.56)

347 (30.31)
318 (27.77)
68 (5.94)
242 (21.14)

204 (27.02)
224 (29.67)
155 (20.53)
127 (16.82)

97 (42.36)
42 (18.34)
10 (4.37)
57 (24.89)

937 (34.64)
811 (29.99)
354 (13.09)
9 (0.33)

Employment
status
Employed
Unemployed
Missing
Income, per year
Mean ($)

1,635 (46.19)
1,534 (43.33)
371 (10.48)

385 (33.62)
432 (37.73)
328 (28.65)

340 (45.03)
318 (42.12)
97 (12.85)

68 (29.69)
112 (48.91)
49 (21.40)

1,147 (42.41)
1,288 (47.61)
270 (9.98)

30,007

31,993

32,513

24,229

24,931

Income groups a
Low
610 (17.23)
135 (11.79)
80 (10.60)
24 (10.48)
639 (23.62)
Middle class 2,268 (64.07) 587 (51.27)
468 (61.99)
145 (63.32)
1,654 (61.16)
High
526 (14.86)
142 (12.40)
125 (16.56)
20 (8.73)
316 (11.68)
Missing
136 (3.84)
281 (24.54)
82 (10.86)
40 (17.47)
96 (3.54)
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
As

seen

from

the

table

above,

majority

of

the

people

in

any

antidepressant/pharmacotherapy group were in the 18-44 years or 45-65 years age group and
were females. In addition, except TCA (49.78% - Blacks), most of the population in any
antidepressant/pharmacotherapy group was White. The marital status and education was varied
across the groups. The distribution between the employed and unemployed groups was uniform.
Majority of the population belonged to middle class income category across all the groups. In
bivariate analyses, all these factors were significantly associated with the class of
antidepressant/psychotherapy at the significance level of 0.05.
Multinomial logistic regression approach produced the results as stated in Table 9 using
‘no depression therapy’ as a comparison group for the outcome variable. People who were above
65 years of age were less likely to receive any antidepressant/ psychotherapy and those between
18-44 years were more likely to receive psychotherapy as compared to those between the age
group of 45-65 years. It was observed that, males were less likely to receive SNRI as compared
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to females. Blacks were less likely to receive SSRI, SNRI or any miscellaneous agent as
compared to Whites. Asians were less likely to receive SNRI, whereas those who reported
multiple races including Hispanic were more likely to report the use of psychotherapy as
compared to Whites. Those who were divorced were more likely to receive any miscellaneous
agent or psychotherapy, whereas those who never married were more likely to receive
psychotherapy as compared to those who were married. Those who reported no education,
elementary/middle school or high school were less likely to receive any treatment for depression
as compared to those who attended college for ≤4 years. Those who attended college for more
than 5 years were more likely to receive any miscellaneous agent or psychotherapy as compared
to those who attended college for ≤4 years. People who were employed were more likely to
receive SSRI, whereas less likely to receive TCA or psychotherapy as compared to unemployed.
Income was

not

significantly associated

with

the likelihood of receiving any

antidepressant/psychotherapy. These results are summarized using OR in Table 9.
Table 9: Multinomial regression results for likelihood of receiving any
antidepressant/psychotherapy
Sociodemographic Factor

Antidepressants (OR, Confidence Intervals)a
SSRI
MA*
SNRI
TCA

Psychotherapy
(OR, Confidence
Intervals)

Age**
18-44 years
>65 years

45-65 years
Males

Females
Blacks
Asians

1.145
(0.966,1.357)
0.842
(0.661,1.073)

1.127
(0.858,1.480)
0.410**
(0.260,0.646)

1.030
(0.776,1.368)
0.504**
(0.288,0.882)

0.802
(0.420,1.533)
0.549
(0.272,1.107)

1.951**
(1.247,3.052)
0.154**
(0.043,0.556)

Reference

Reference

Reference

Reference

Reference

0.898
(0.777,1.038)
Reference
0.476**
(0.377,0.601)
0.859
(0.454,1.626)

Gender**
1.175
0.686**
(0.913,1.513) (0.521,0.902)
Reference
Reference
Race**
0.415**
0.297**
(0.271,0.636) (0.169,0.523)
0.925
0.128**
(0.366,2.337) (0.017,0.983)
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0.758
(0.425, 1.351)

1.119
(0.753, 1.662)

Reference

Reference

0.575
(0.316,1.039)
0.983
(0.129,7.481)

0.573
(0.316,1.039)
2.658
(0.871,8.113)

Multiple Races
reported
Whites

0.804
(0.521,1.241)
Reference

Widowed

0.891
(0.667,1.192)
0.817
(0.674,0.991)
0.823
(0.572,1.184)
0.907
(0.744,1.106)

Divorced
Separated
Never Married

Married
No education
Elem/ Mid
School
High school
5+ Years College
≤ 4 Years College
Employed

Reference
0.210**
(0.060,0.737)
0.593**
(0.431,0.814)
0.838**
(0.722,0.974)
1.094
(0.833,1.437)
Reference
1.378**
(1.149,1.652)

Unemployed

Reference

Low income

1.184
(0.933,1.503)
1.042
(0.845,1.285)
Reference

High income

0.977
0.384
(0.357,2.673) (0.139,1.063)
Reference
Reference
Marital Status**
1.166
0.779
(0.745,1.824) (0.454,1.335)
1.432**
1.027
(1.013,2.025) (0.725,1.456)
0.772
0.561
(0.346,1.721) (0.256,1.229)
1.257
0.854
(0.911,1.733) (0.583,1.252)

0.276
(0.038,2.028)
Reference

2.725**
(1.140,6.511)
Reference

1.070
(0.469,2.439)
1.043
(0.541,2.013)
0.461
(0.098,2.178)
1.396
(0.646,3.018)

1.217
(0.285,5.196)
2.412**
(1.416,4.108)
1.694
(0.443,6.470)
2.775**
(1.646,4.680)

Reference
Reference
Education**
0.750
0.088**
(0.180,3.127) (0.012,0.668)
0.506**
0.492**
(0.300,0.855) (0.283,0.858)
0.626**
0.584
(0.472,0.830) (0.433,0.788)
1.835**
0.851
(1.194,2.821) (0.511,1.417)

Reference

Reference

N/Ab
1.728
(0.731,4.087)
0.818
(0.442,1.514)
1.143
(0.374,3.497)

0.072**
(0.009,0.532)
0.697
(0.259,1.871)
0.759
(0.480,1.199)
2.183**
(1.210,3.936)

Reference

Reference

0.518**
(0.284,0.945)

0.520**
(0.303,0.892)

Reference

Reference

0.496
(0.216,1.140)
1.099
(0.469,2.573)
Reference

0.776
(0.428,1.406)
1.560
(0.821,2.966)
Reference

Reference
Reference
Employment status**
0.960
0.804
(0.695,1.327) (0.570,1.133)
Reference
Reference
Incomec
1.007
0.833
(0.676,1.500) (0.489,1.416)
0.946
1.251
(0.663,1.350) (0.875,1.788)
Reference
Reference

Middle class
income
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
a
The reference class for therapy was getting no antidepressants/pharmacotherapy at all
** - Significant results
b
- N/A – Not applicable, since there were almost no patients in that group and the sample size
for that cell was < 5, the OR obtained for that particular group were absurd
c
- Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
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Type 3 analysis effects of multinomial logistic regression suggested that all the
sociodemographic factors, except income, were significantly associated with the class of
antidepressant/psychotherapy. The odds ratios suggested that age, employment and education
were the most significantly associated factors. The percentages of those who are in that
particular sociodemographic characteristic across the classes of antidepressants/ psychotherapy
are represented graphically in Figure 7.
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous agents
Figure 7: Most significantly associated sociodemographic characteristics

As seen from the graphs and the findings above, SSRI and psychotherapy have a higher
percentage of people in the age group of 18-44 years where as all the other groups have a higher
percentage of people in the age group of 45-65 years. Looking at the employment status, SSRI
and SNRI have a higher proportion of employed people whereas other groups have a higher
proportion of unemployed people. On comparing the education received in every group, it was
observed that SNRI had the highest proportion of people who completed college where as all
others had highest proportion of people who completed high school.
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Section 3.3: Discussion
The study thus suggested that in majority of cancer patients in the US, depression was
untreated. Out of those treated, antidepressants were prescribed more frequently (32%) than
psychotherapy (15%). SSRI was the most frequently prescribed class of antidepressant with or
without psychotherapy followed by miscellaneous agents. Around 7.25% patients were
prescribed psychotherapy and an antidepressant both. Some antidepressants were also
prescribed in combination with one another. SSRI along with a miscellaneous agent was the
most commonly prescribed combination of antidepressants. The finding of SSRI being the most
commonly prescribed antidepressant was consistent with the findings found in the previous
literature where, prescribing of SSRI occurred in most of the patients, along with SNRI. 18,21
However, one of these studies was conducted only in ambulatory cancer patients18 and the other
one was not in general population.21 Also, with respect to antidepressants, exposure to
SSRI/SNRI was the only outcome considered and comparison to other classes was not
considered. In our study, it was also found that out of all the comorbidities included, arthritis
and high blood pressure were the most commonly associated along with cancer and depression
and most of the people had two comorbidities associated. These were consistent with the
findings in the literature, where a majority of patients also reported asthma.30,39
The quantity of prescribed drugs and the days supplied per prescription were not found
to be significantly different from one another in this study across the classes of antidepressants.
However, numerically, the quantity was found to be lowest whereas the days supplied per
prescription were found to be the highest for SSRI as compared to other antidepressant classes.
Higher quantities of SSRI were reported to be associated with abnormal heart rhythms, which
could be the reason for the quantity of SSRI prescribed being lower. 41 In addition, the frequency
of dosing was lower (usually once per day as opposed to 2 times in a day) which could be the
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reason for days supplied being maximum for SSRI.41 Hence, the findings were in compliance
with the reported dosing requirements for SSRI.
The trends in antidepressant use suggested that throughout the study period SSRI was
the most frequently prescribed class. The use of miscellaneous agents and psychotherapy has
eventually increased. The spike in the prescription of SNRI in the year 2008 could be because
of FDA approval of Desvenlafaxine and some other SNRI with lower side effects. 42 The
findings of increase in SSRI use were consistent with the findings of a previous study conducted
by Kantor et al.43 This study however, looked at the trends in overall prescription of SSRI only
from 1999 to 2012 in general population.43 There have been some articles discussing side effects
of TCA. These are higher than those associated with other classes, TCAs are also associated
with many drug-drug interactions and hence their use has gone down over a period of time and
if prescribed, the patients have to be thoroughly monitored.44-47
On comparing the sociodemographic factors, it was found that all of them individually
were significantly associated with the class of antidepressant/psychotherapy. On conducting for
other factors, income was found to be non-significant. Age, employment status and education
were found to be the most significant factors. It was suggested that, people who were above 65
years of age were less likely to receive any therapy as compared to those who were below 65
years. This is consistent with the past findings of a study where patients <55 years were more
likely to receive any antidepressant. However, as mentioned earlier this study only consisted of
ambulatory

cancer

patients

and

did

not

compare

various

classes

of

antidepressants/psychotherapy.18 A study conducted by Waitzfelder et al. has also suggested
that patients aged > 60 years had lesser odds of initiating depression treatment. However, this
study was in general population, and there has not been any other study looking specifically at
cancer patients.48 Studies have shown that females are more likely to be treated for depression
than males, this complies with the regression results of our study.49 Those who were employed
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were

more

likely

to

receive

SSRI

and

less

likely

to

receive

any

other

antidepressant/psychotherapy as compared to unemployed.
There are several limitations for this study. Firstly, it was a retrospective cross-sectional
study and hence causality could not be assigned. The associations found with the
sociodemographic factors could not be proven to be true over a longitudinal duration. In
addition, it is possible that some patients were later switched to another class of
antidepressant/psychotherapy, different than the one to begin with or the one that was reported
in MEPS, these would not be captured in the dataset, since it was not longitudinal. Also, since
the date of prescription fill was not captured under MEPS. It is possible that some patients were
switched within 3 months (one round) to another class of antidepressant but in our study, they
were captured as combinations of antidepressants. Secondly, the prescription of any class of
antidepressant or psychotherapy and the demographics associated with each could also depend
on the stage of cancer which due to the data source limitation could not be controlled. Thirdly,
since the survey was patient-reported there could also be some recall bias involved.
Despite the limitations stated above, this study adds to the past literature by providing
certain novel findings. Patterns of use across classes of antidepressants/ psychotherapy or the
predictors associated with each class had not been explored amongst cancer patients with
depression using a nationally representative sample in the past studies. A study conducted by
Fisch et al. identified the predictors of antidepressant use, however, if these persist across all
the antidepressant classes and psychotherapy or differ had never been studied.18 This study
states that these predictors differ by classes, which increases the significance of our results. In
addition, prescription trends have been identified for antidepressants in general, this study adds
more to it by looking at trends per class of antidepressant and also comparing it with
psychotherapy.17 This study also produces a framework for conducting future studies where,
significant sociodemographic factors and predictors identified could be studied in depth.
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CHAPTER IV: SPECIFIC AIM II
Aim 2: To compare costs and healthcare utilization (office-based visits) of cancer patients
across different classes of antidepressants in the US
A: To compare the prescription medicines expenditures, overall costs and out of pocket
expenses of cancer patients with comorbid depression across different classes of
antidepressants
B: To compare office-based visits with the expenses related to these across cancer
patients along with comorbid depression classified based on the class of antidepressants
Section 4.1: Methods
Data source and study design:
As mentioned above, it was a cross-sectional retrospective study conducted using
Medical Expenditure Panel Survey. For this specific aim, along with full year consolidated files
for demographics and medical condition files for sample selection, prescription medicine files
and office-based visits files were mainly used to identify the costs associated with each of the
antidepressant class and psychotherapy. The study sample was same as specific aim 1 with
17,671 patients diagnosed with cancer along with a comorbid depression condition.
Variables:
Demographics and controlling factors:
Aim 1 identified that almost all the sociodemographic characteristics were associated
with the use of antidepressants. Age, gender, race, marital status, education, employment status
and income were thus the demographic factors that were obtained from the full year
consolidated files, were recoded as mentioned in aim 1, and were controlled for while comparing
costs along with the associated comorbidities. The study also controlled for the overall health
status of the patients since that could affect the frequency of dosing of antidepressants and some
cost and utilization outcomes across all the groups. This variable was obtained from the full
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year consolidated files as well. MEPS captures the overall health status of the patients into 5
main categories namely: “excellent”, “very good”, “good”, “fair” and “poor”. It is a variable
captured from the short form-12 version 2 (SF-12), self-assessment questionnaire (SAQ).
Prescription medicine costs:
The costs associated with prescription medicines per purchase/fill were captured from
the prescription medicines files from January 2005 to December 2015. MEPS reports the total
amount per patients and the sources of payment for the same. These costs were associated with
each prescription fill per month. For the prescription medicine costs purposes, psychotherapy
alone was not considered as a treatment arm, since they did not have any antidepressants
prescribed. The costs were thus compared against the 4 major classes of antidepressants and
those who were prescribed psychotherapy and antidepressants both. Other than the total costs,
the amount paid out of pocket and by private insurance was also compared across these classes,
since these two were the major sources of payments identified. New variables were created to
indicate the patients who paid out of pocket entirely and for those who paid using out of pocket
and private insurance both. Other sources of payment such as Tricare, Veterans Insurance, other
state and local government insurance, Medicare and Medicaid were also included to assess the
proportion of patients who used these as their sources of payment.
Office-based visits frequency and costs:
Similar to prescription medicines costs, similar variables were obtained from the officebased visits files. As mentioned above, psychotherapy visits were identified by using modified
clinical classification codes for office-based visits (657-psychotherapy/mental counseling
visits), ‘Type of Medical person the patient talked to on the visit’ (10 = Psychologist) and ‘Best
category for care the patient received on visit’ (4 = Psychotherapy/Mental Health Counseling).
The frequency/number of visits were identified across the classes of antidepressants. Other
categories for office-based visits like general checkup, treatment/diagnosis purposes which were
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used the most were also identified across the classes of antidepressants. The costs associated
with these visits, mainly psychotherapy, were obtained from the office-based visits files from
January 2005 to December 2015. The costs captured by MEPS were the costs per visit. The
sources of payment for these visits were also identified. Similar to prescription medicines, out
of pocket and private insurance were the two main sources of payment. New variables in this
case were created too, indicating those who paid entirely out of pocket and those who paid using
private insurance and out of pocket both. Variables for other sources such as Tricare, Veterans
insurance, other state and local insurance, Medicare and Medicaid were also used to assess the
proportion of patients who used these sources of payments. For aim 2B, the costs and the
frequency of psychotherapy visits were compared across 5 main classes: SSRI, miscellaneous
agents, SNRI, TCA and psychotherapy only.
Statistical Analyses:
All the analyses for this aim, was conducted on patient-level files created by
summarizing the event-level files. The costs were summarized per patient using PROC
MEANS. In order to summarize the office-based visit categories per patient, PROC
TRANSPOSE was used. Means were used to summarize total prescription costs and total costs
per visits across different classes of antidepressants. Frequencies/ proportions were used to
calculate the number of psychotherapy visits across classes of antidepressants. While calculating
means for out of pocket costs and private insurance, non-positive values were excluded to avoid
the skewing of mean. There were no non-positive values for total costs since all the patients
had some costs, however there were non-positive zero out of pocket (15% patients) and private
insurance (9% patients) prescription costs and non-positive zero out of pocket (7% patients) and
private insurance (11% patients) office-based visit costs based on the patient’s source of
payment. The means were calculated separately for those who paid out of pocket completely
and for those who paid using both the sources namely, by private insurance and by out of pocket.
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These means were calculated by restricting the analyses to patients who were identified using
new variables (indicating if they paid out of pocket entirely or by using both the sources). These
means (out of pocket only, out of pocket when accompanied by private insurance and out of
pocket and private insurance both) were compared using graphs. While calculating costs for
office-based visits, only patients with psychotherapy as an office-based visit were included.
Those who had general checkups and treatment as reasons for office-based visits were excluded
so the costs obtained could be associated with psychotherapy alone. ANOVA approach was
used to conduct unadjusted analyses and to assess if there is a difference in total mean costs
across antidepressant classes. All the means calculated were weighted using PROC
SURVEYMEANS. In order to conduct adjusted regression analyses, PROC GLM was used.
The distribution of total cost was non-normal and it had unbalanced variances, generalized linear
model was thus used to conduct the analyses. Adjusted costs were then calculated by
exponentiating the parameter estimates obtained from the generalized linear model using the
log link function. PROC GLM was also used to conduct regression analyses on costs paid out
of pocket and by private insurance. The GLM model used for all the costs was as follows:
Ŷ = β0 + β1 . Age + β2 . Gender + β3 . Race+ β4 . Marital Status + β5 . Education +
β6 . Employment Status + β7 . Income + β8 . Overall Health Status + β9 . Comorbidities +
β10 . Number of comorbidities + β11 . Antidepressant/Psychotherapy prescribed+ Ɛa
Ŷ- Total prescription/ office-based visits/out of pocket/ private insurance costs
All the analyses were conducted at a significance level of 0.05. The hypothesis tested in
this analysis was that the prescription and office-based visit costs would differ significantly
across the groups. The analyses were conducted using SAS v9.4 and MS Excel 2016 was used
to plot graphs.

47

Section 4.2: Results
Aim 2A: To compare the prescription medicines expenditures, overall costs and out of
pocket expenses of cancer patients with comorbid depression across different classes of
antidepressants
To assess the economic burden on cancer patients mainly because of depression,
prescription and office-based visit costs were compared across different classes of
antidepressants and psychotherapy. The results for mean prescription costs are summarized in
Table 10.
Table 10: Per fill total prescription costs across depression therapy classes
Therapy Class
Sample
Mean ($ per
Std
95% CL for Mean
Size
fill/purchase) Error of
Mean
SSRI
3,401
68.34
2.0812
64.23
72.44
MA*
1,098
79.84
5.0571
69.90
89.77
SNRI
730
132.28
6.5123
119.49
145.08
TCA
224
39.96
3.3478
33.39
46.52
Both
1,278
67.15
4.1117
66.94
93.10
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA*- Miscellaneous Agents
Both – Antidepressant and psychotherapy
The prescription costs per purchase were the highest for SNRI (mean= $132.28). These
findings were consistent with the prices reported earlier where SNRI had the highest prices
reported. ANOVA test suggested that the cost for SNRI and TCA differed significantly from
each other and from all other classes at a p-value of 0.05. The source of payment for total costs
were further studied across 4 major classes of antidepressants. Most of the share of total
prescription cost was paid either completely out of pocket or by out of pocket and private
insurance both. There were around 48.87%, 43.06%, 49.80%, 34.06% of patients receiving
SSRI, miscellaneous agents, SNRI and TCA respectively who reported a combination of both
out of pocket and private insurance as sources of patients. Around 19.29%, 13.71%, 13.25%,
17.90% patients receiving SSRI, miscellaneous agents, SNRI and TCA respectively reported
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only out of pocket, others reported state and local government insurance, Tricare, Veterans
insurance or other combinations. Around 6-6.5% patients in every group also reported using
Medicaid as a source of payment, whereas there were very few reporting Medicare. The out of
pocket mean values (mean of positive values, excluded the patients who had non-positive costs)
for patients who paid entirely out of pocket, the mean share of out of pocket costs when
accompanied by private insurance and the total mean costs for patients who paid entirely using
out of pocket and private insurance both are summarized in Figure 8.
Mean Costs by Antidepressant Class
128.35

140
120
100
80
60
40

78.7
64.84
44.92
35.07

50.19
48.83

75.78
41.2

33.77

36.37
22.8

20
0
SSRI

MA*

SNRI

TCA

Out of pocket(mean)
Out of pocket when accompanied by private insurance**(mean)
Both sources***(mean)

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
** The share of out of pocket costs when the source of payment was out of pocket
and private insurance both
*** The total cost paid by private insurance and out of pocket

Figure 8: Mean costs paid out of pocket and by private insurance across classes of
antidepressants
As seen from the findings above, all costs, except the share of out of pocket when
accompanied by private insurance (highest for miscellaneous agents), were the highest for
SNRI. The mean costs associated with both sources (out of pocket and private insurance) were
similar to the means reported above in Table 10 since that was the source of payment in majority
of patients in all the groups. As expected, the out of pocket costs were significantly lower when
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a share was also paid by private insurance in the SSRI, SNRI and TCA groups, whereas it was
almost the same in the miscellaneous agents group. These costs reported were mean costs
without controlling for other factors. An adjusted regression analyses was then conducted using
generalized linear models controlling for demographics and the overall health status. Regression
results for total costs paid by the patients across classes of antidepressants using generalized
linear models are summarized in Table 11.
Table 11: Regression results for total prescription costs
Predictors
Intercept*

Estimate

Standard Error

t Value

p-value

62.20582066

24.7190825

2.52

0.0119

Age Groups
18-44 years

-6.92739417

3.6807988

-1.88

0.0599

>65 years

-3.65931933

5.0099021

-0.73

0.4652

-

-

-

-

12.30309422

3.3529060

3.67

0.0002

-

-

-

-

45-65 years

Gender*
Males
Females

Race
Blacks

3.71937511

4.5828044

0.81

0.4171

Asians

-11.28274071

13.6726905

-0.83

0.4093

Multiple races

-11.17445652

9.6305885

-1.16

0.2460

-

-

-

-

Whites

Marital Status
Widowed

0.36601644

5.8745367

0.06

0.9503

Divorced

-9.18654975

4.1045221

-2.24

0.0252

Separated

0.83341885

7.5886217

0.11

0.9126

Never married

5.89124176

4.2672297

1.38

0.1675

-

-

-

-

Married
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Education*
No education

-22.67872928

21.1740225

-1.07

0.2842

Elem/Mid School

-16.34956478

6.0321145

-2.71

0.0067

High school

-3.19607752

3.4618290

-0.92

0.3559

5+ years college

5.30329548

6.2251900

0.85

0.3943

≤4 years college

-

-

-

-

Employment Status
Employed
Unemployed

-6.29026083

3.8528733

-1.63

0.1026

-

-

-

-

Incomea
Low

-3.13492511

4.8804709

-0.64

0.0599

High

9.10056345

4.9352345

1.84

0.0652

-

-

-

-

Middle class

Overall Health Status
Excellent

-1.37070499

8.2432892

-1.62

0.1048

Very good

-10.32440132

6.2116093

-1.66

0.0965

Good

0.42975078

5.6753561

1.49

0.1375

Fair

-7.40559351

5.6348821

-1.31

0.1888

Poor

-

-

-

-

Comorbidities
Asthma

2.25400711

5.1539475

0.44

0.6619

Arthritis

-11.31680318

3.9533362

-0.33

0.7391

Diabetes

-8.40233433

8.4895345

-0.99

0.3223

High blood pressure

-9.85627442

5.6943373

-1.73

0.0835

-

-

-

-

None

Number of Comorbidities
2
≥3

15.64873631

13.0680208

0.43

0.6656

-

-

-

-

Antidepressant/Psychotherapy*
SSRI

27.82665706

19.8866508

1.40

0.1618

MA**

30.76547665

20.6221038

1.49

0.1358

SNRI

63.21644585

20.7578952

3.05

0.0023
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TCA

-6.33866732

23.2797759

-0.27

0.7854

Both***
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants MA** - Miscellaneous
Agents, Both*** - Antidepressant and psychotherapy
*Significant predictors
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
Thus, as seen from the regression results, the total mean costs per prescription increases
when SSRI, miscellaneous agent or SNRI is prescribed as compared to both (antidepressant and
psychotherapy) being prescribed. These findings are consistent with the mean of total
prescription costs reported above in table 10 where the means for SSRI, miscellaneous agents
and SNRI are higher than the mean when both the therapies are prescribed. The total adjusted
mean costs per prescription are summarized in Table 12, and these were the highest for SNRI
($112.92). On regressing the costs paid out of pocket against the predictors, these increased for
SSRI and SNRI whereas decreased for TCA and miscellaneous agents as compared to those
who were prescribed both the therapies. On regressing the costs paid by private insurance
against the predictors, these increased for all the classes of antidepressants as compared to both
the therapies being prescribed. These results
are summarized in Appendix Tables 2 and 3.
Table 12: Adjusted per fill total prescription costs across depression therapy classes
Therapy
Sample Mean ($ per
Std Error of
95% CL for Mean
Class
Size
fill/purchase)
Mean
SSRI
3,397
77.06
0.332020
76.409347 77.714610
MA*
1,072
80.84
0.724687
79.419274 82.268223
SNRI
713
112.92
0.722216
111.502743 114.341979
TCA
217
44.31
1.366258
41.628754 46.999902
Both
1,139
51.35
1.644457
48.122168 54.586994
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA*- Miscellaneous Agents
Both – Antidepressant and psychotherapy
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Aim 2B: To compare office-based visits along with the expenses related to these across
cancer patients with comorbid depression classified based on the class of antidepressants
Office-based visits are more common in cancer patients since they have more frequent
general checkups and require psychotherapy or mental health counseling more often than those
who do not have cancer. In this study, out of all the office-based visits, psychotherapy/ mental
counseling and the costs related to these were studied in depth, since these are used frequently
to manage depression amongst cancer patients. These costs were studied across different classes
of antidepressants and those receiving psychotherapy alone. Table 6 above, summarizes the
number of patients using psychotherapy along with antidepressant, which suggests that 47.39%
(n=1282) of patients using psychotherapy use it along with an antidepressant whereas 52.60 %
(n=1423) use it alone. Table 13 below summarizes the total number of office-based visits across
class of antidepressants including psychotherapy the other categories.
Table 13: Office-based visit category by class of antidepressant
Visit category
SSRI (n, %)
MA* (n, %)
SNRI (n, %)
TCA (n, %)
General checkup 1,338 (31.97) 399 (27.74)
265 (27.31)
79 (29.15)
Treatment
1,881 (44.95) 621 (43.18)
453 (46.70)
137 (50.55)
Psychotherapy
733 (17.51)
338 (23.50)
182 (18.76)
29 (10.70)
Other
232 (5.54)
80 (5.56)
70 (7.21)
26 (9.5)
Total
4,184 (100%) 1,438 (100%) 970 (100%)
271 (100%)
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
Miscellaneous agents thus had the highest percentage of patients reporting the use of
psychotherapy/counseling in order to manage depression. General checkups, treatment purposes
(which could either be receiving any treatment or discussing the options) and psychotherapy
were the major reasons for office-based visits amongst cancer patients with depression. The
other visit categories for patients receiving psychotherapy alone are reported in Figure 9.
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Office-visits categories
11%

17%

8%

31%
33%

General Checkup

Treatment

Follow-up visit

Other

None

*Percentages calculated are over n=1423 (sample size for psychotherapy alone)
Figure 9: Classification of office-based visits for those receiving psychotherapy alone
As seen from the figure above, patients receiving psychotherapy alone, also had
some other office-based visits, majority of which were either for treatment or follow-up
purposes. There were around 11% (n=159) patients who did not report any office-based visit
other than that for psychotherapy/mental health counseling. The study sample was then
restricted to patients receiving psychotherapy as an office visit only so the costs could be
associated mainly with psychotherapy and reduce bias due to costs associated with other
categories of visits. The total costs associated mainly with psychotherapy/counseling across the
classes of antidepressants and with psychotherapy alone are reported in Table 14.
Table 14: Total mean costs associated per visit across class of antidepressants and psychotherapy
alone
Combination with
psychotherapy

Sample
size

Mean
($/visit)

Std Error of
Mean

95% CL for Mean

SSRI

713

121.42

4.8781

111.81

131.04

MA*

254

156.15

18.3303

120.03

192.28

SNRI

131

139.63

15.8467

108.40

170.87

TCA

19

131.25

36.6650

58.99

203.51

Psychotherapy alone

626

147.40

16.2409

115.33

179.48

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA*-Miscellaneous Agents
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These costs did not differ significantly from each other. However, miscellaneous agents
had a slightly higher cost associated with the visit followed by psychotherapy alone. Most of
the share of total office-based visit costs was paid either completely out of pocket or by out of
pocket and private insurance both. There were around 39.55%, 33.85%, 44.27%, 31.58% and
36.58% patients receiving SSRI, miscellaneous agents, SNRI, TCA and psychotherapy alone
respectively who reported a combination of out of pocket and private insurance as sources of
payment. Around 8.97%, 5.11%, 6.62%, 5.26% and 13.26% patients receiving SSRI,
miscellaneous agents, SNRI, TCA and psychotherapy alone respectively reported only out of
pocket, others reported state and local government insurance, Tricare, Veterans insurance or
other combinations. Medicare/ Medicaid was not reported as a source of payment for
psychotherapy/ counseling visits by any of the patients. The mean values (mean of positive
values, excluded the patients who had non-positive costs) paid by private insurance, out of
pocket and by private insurance and out of pocket both are summarized in Figure 10.

Mean Costs by Antidepressant/psychotherapy Class
279.75

300
250

187.79

200
150
100
50

108.11
68.25
35.01

72.95

182.7

76.68
42.93

165.39

60

42.63

177.59

81.1
47.31

0
SSRI

MA*
Out of pocket(mean)

SNRI

TCA

Psychotherapy
alone

Out of pocket when accompanied by private insurance**(mean)
Both sources***(mean)

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - SerotoninNorepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
** The share of out of pocket costs when the source of payment was out of pocket and
private insurance both
*** The total cost paid by private insurance and out of pocket
Figure 10: Mean costs paid out of pocket and by private insurance across classes of
antidepressants/psychotherapy
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As seen from the findings above, on excluding the non-positive values, the means
(both sources) for certain classes of antidepressants were slightly higher than the total mean
costs reported in Table 14. All the mean costs for office-based visits were higher for those
receiving miscellaneous agents. This was consistent with the findings above, where the total
mean costs were the highest for miscellaneous agents. The mean cost for those paying entirely
out of pocket were considerably higher for those receiving miscellaneous agents (mean =
$279.75 per visit). As expected, the out of pocket costs significantly reduced in all the groups
when accompanied by private insurance. Since, out of pocket and private insurance were the
major sources of payment in most of the population, the trends observed for mean costs (both
sources) were similar to that obtained for total mean costs with SSRI being associated with the
lowest cost and miscellaneous agents being associated with the highest costs.
Regression was conducted using total costs per visit as the outcome variable and
regressing against the predictors including the demographic variables, overall health status,
number and type of comorbidities. On adjusting for other factors, the class of antidepressant
was not significantly associated with the visit cost. These results were similar to the unadjusted
results where the cost differences were not significant across the depression therapy classes. The
costs however numerically reduced the most for SSRI (estimate = -54.73, p-value = 0.0171)
followed by miscellaneous agents (estimate = -25.21, p-value = 0.4075), SNRI (estimate = 11.41, p-value = 0.7461) and TCA (estimate = -0.96, p-value = 0.9895) as compared to
psychotherapy alone, which was consistent with the unadjusted mean costs, where the
unadjusted costs associated with psychotherapy alone were higher than the other classes. These
results are summarized in Appendix Table 4. Table 15 below summarizes the adjusted costs for
office-based visits, mainly psychotherapy.
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Table 15: Adjusted total mean costs associated per visit across class of antidepressants and
psychotherapy alone
Combination with
psychotherapy

Sample
size

Mean
($/visit)

Std Error of
Mean

95% CL for Mean

SSRI

707

110.28

2.730

104.34

116.23

MA*

247

139.42

5.778

126.83

152.01

SNRI

129

141.20

5.755

128.66

153.74

TCA

19

165.84

17.263

128.23

203.45

Psychotherapy alone
619
166.39
3.488
144.79
169.92
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA*-Miscellaneous Agents
On controlling for other factors, the costs associated were the highest for those
who received psychotherapy alone where as they were lowest for those receiving SSRI. The
trends seen in these adjusted costs were thus different on controlling for other factors.

57

Section 4.3: Discussion
It was seen from the results that the total mean prescription costs associated per month
were the lowest for TCA and the highest for SNRI. The findings of SNRI being associated with
highest costs were consistent with the prices reported earlier under ‘Introduction’, where SNRI
had highest out of pocket price for 30 tablets.23 In addition, a study conducted by Khandker et
al. also suggested that the patients who switched from an SNRI to SSRI eventually had lower
pharmacy and medical costs.50 This study also suggested that, switching classes of
antidepressants was rare and patients who made a switch had higher all-cause healthcare costs
and higher depression-related costs. This study was however conducted in non-cancer patients.50
In our study, the total mean adjusted prescription costs were higher when SSRI, miscellaneous
agents or SNRI was prescribed as compared to prescribing any antidepressant along with
psychotherapy. These results were consistent with the unadjusted analyses findings, where the
costs of the above-mentioned classes were higher than that when accompanied by
psychotherapy. These findings were in contrast to that obtained in a study conducted by Shen
et al.51 and Alwhaibi et al.,25 where in, the costs associated with psychotherapy along with
antidepressant or alone were higher than that associated with only antidepressant use. However,
these were total expenditures per patient and not just prescription costs, also these studies were
either restricted to a specific type of cancer25 or were not in cancer population at all.51 In our
study, it was also observed that most patients reported a combination of private insurance and
out of pocket both as sources of payment for prescription medicines. Some also reported
Medicaid or out of pocket entirely as a source of payment. There have not been any studies prior
to this looking at sources of payment for depression therapies amongst cancer patients with
depression. However, American Cancer Society suggests that, most of the cancer patients report
private insurance as their source of payment (44%) for the total costs that are incurred during
the cancer treatment.5 A study conducted by Iadeluca et al. also suggested that prescription
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medications and office-based visits were the main cost drivers in their cancer population,
however they were looking at cancer in general and not depression specifically.32
With respect to costs associated with office-based visits mainly psychotherapy, it was
observed that miscellaneous agents had slightly higher unadjusted costs of these visits compared
to other classes and psychotherapy alone. Miscellaneous agents also had the highest percentage
of patients within this group requiring psychotherapy. The adjusted costs were the highest for
those receiving psychotherapy only without any antidepressant, these findings were similar to
the results of a study conducted by Alwhaibi et al.,25 where psychotherapy higher associated
costs as compared to antidepressants only. These costs for psychotherapy visits could differ
slightly because of the type of credentials the therapist has, the cost of running the office, the
type of practice (community mental health or private practice) or the services offered during
these visits and the intensities of these.52 These visit costs were paid by a combination of private
insurance and out of pocket both by most of the patients. Medicare/ Medicaid was not reported
as a source of payment. There have not been any studies conducted yet looking at costs
associated with office-based visits mainly psychotherapy. The results were consistent with a
study conducted by Chung which suggested that utilization of SSRI led to a reduction in overall
outpatient visits and other prescription drugs however, this study was not restricted to cancer
patients and the comparison group consisted of people only taking TCA.53 There have however
not been any studies comparing office-based visit costs across classes of antidepressants/
psychotherapy amongst cancer patients with depression.
Our study however, has certain limitations. In addition to the limitations stated above,
certain cost specific limitations were identified. Firstly, the prescription costs associated could
not be restricted completely to antidepressants only. The patients were also taking some other
medicines such as painkillers, blood pressure or cholesterol medications; however, these were
minimum and evenly spread across all the classes. Secondly, the prescription costs were
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associated per purchase/fills per month. However, MEPS does not capture the number of fills
associated per person in a month. The total costs thus per month could differ based on the
number of fills that were associated with patients taking any particular medication. Thirdly,
when office-based visit costs were compared, these could differ based on the therapist charges,
which is subjective and could not be controlled for in the study. Finally, since the study was not
prospective, any further changes in the therapy and thus the cost could not be tracked.
Despite the limitations mentioned above, the study has a lot of significance. None of the
studies conducted prior with respect to depression amongst cancer patients have looked at costs
associated with individual therapies. This study thus adds to the literature. There have been cost
effective analysis studies of certain non-pharmacotherapy interventions such as telecare, home
care, inpatient care and psycho-educational interventions; however, none of them have
compared classes of antidepressants along with psychotherapy.33,34 There have also been studies
looking at total expenditure in cancer patients with no depression treatment versus only
antidepressants versus only psychotherapy however, these have not looked at prescription costs
separately or compared costs across classes of antidepressants separately.24 In addition, the
population in some of these studies was restricted only to specific types of cancer. There have
also been no studies looking at office-based visit utilization and the costs associated with these
across classes of antidepressants. This study is thus novel in producing such findings and forms
the basis for future studies to be conducted with respect to cost comparisons. Total healthcare
costs could be studied across classes of antidepressants. Conducting future studies addressing
the limitations above would produce more robust results which could help in guiding formulary
or coverage decisions based on the cost findings.
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CHAPTER V: SPECIFIC AIM III
Aim 3: To compare quality of life (QOL) of cancer patients in the US with comorbid
depression across different classes of antidepressants and psychotherapy
A: To compare the physical and mental component score (PCS/MCS) across different
classes in order to assess quality of life of cancer patients with comorbid depression
B: To compare Patient Health Questionnaire – 2 (PHQ-2) scores and the frequency of
depression obtained from Short Form version 12 (SF-12) to assess quality of life of
cancer patients with comorbid depression
Section 5.1: Methods
Data Source and Study Design:
As mentioned earlier, it was a cross-sectional retrospective study conducted using
MEPS. For this aim, office-based visit files were needed for identifying psychotherapy visits.
All the main outcome variables were captured from the full year consolidated files. Prescription
medicine files were used to identify patients in each class of antidepressant. The sample size
was same as the first two aims with 17,671 patients diagnosed with cancer along with a
comorbid depression condition.
Variables:
Demographics and controlling factors:
Similar to aim 2, age, gender, race, marital status, education, employment status and
income were the demographic factors, overall health status (from SF-12 SAQ), comorbidities
and number of comorbidities were the variables that were controlled for in the study. All these
variables were obtained from full year consolidated files.
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Quality of life variables:
All quality of life variables were obtained from the full year consolidated files. Physical
and Mental Component Scores (PCS and MCS) are the continuous variables captured by MEPS
using SF-12 SAQ. The SF-12 measures eight constructs: physical functioning, role limitations
resulting from physical health problems, bodily pain, general health, vitality (energy/fatigue),
social functioning, role limitation resulting from emotional problems, and mental health. MEPS
imputes these into physical and mental domains and rescales the scores with a maximum
average of 50.28 A higher physical/mental score indicates a better functioning and thus a better
quality of life. MCS is mainly indicative of depression and mental health, however both the
scores were used for this study’s purposes. PCS/MCS are mainly indicative of Health Related
QOL (HrQOL). These scores were compared across different classes of antidepressants and
psychotherapy, the scores across the combinations of antidepressants identified in aim 1 were
compared too. For aim 3b, PHQ-2 scores were used to assess quality of life. These were obtained
from the patient health questionnaire. The PHQ-2 is made up of 2 items and the scores range
from 0 to 6. A higher PHQ-2 score indicates a greater tendency towards depression. A lower
score thus implies lower depression and hence a better quality of life. A categorical variable
indicating the frequency of depression in a week was used too. This variable has 4 levels for the
frequency namely: “0-Not at all”, “1-Several Days”, “2-More Than Half The Days” and “3Nearly Every Day”. This variable was a part of SF-12 Self-Assessment Questionnaire – 2 weeks
(SAQ-2 Wks). The PHQ-2 scores and frequency of patients belonging to each category of
depression frequency were compared across different classes of antidepressants, psychotherapy
and combinations of antidepressants.
Statistical Analyses:
Means were used to summarize the PCS, MCS and PHQ-2 scores. Frequencies/
proportions were used to identify the percentages of patients in each of the categories for the
depression frequency variable across the classes of antidepressants. The mean scores were
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compared across individual classes, psychotherapy alone and combinations of antidepressants.
The unadjusted comparison was conducted using PROC ANOVA. In order to compare the QOL
outcomes of combinations of antidepressants against the individual classes, means were
calculated for each group. A mean PCS/MCS/PHQ-2 score was calculated for those using any
combination of antidepressants and this was compared against the mean score of those using
individual classes using t-test. All these means were weighted and calculated using PROC
SURVEYMEANS. Since, the scores had a normal distribution, PROC SURVEYREG was used
to conduct adjusted regression analyses on PCS and MCS and PHQ-2 scores. The mean PHQ2 scores were also compared using graphs. The model used for regression was as follows:
Ŷ = β0 + β1 . Age + β2 . Gender + β3 . Race+ β4 . Marital Status + β5 . Education +
β6 . Employment Status + β7 . Income + β8 . Overall Health Status + β9 . Comorbidities +
β10 . Number of comorbidities + β11 . Antidepressant/Psychotherapy prescribed+ Ɛa
Ŷ- PCS/MCS/PHQ-2 Score
The categorical variable for depression frequency was compared using chi-square test
obtained from PROC SURVEYFREQ. Adjusted analyses was carried on the same using PROC
SURVEYLOGISTIC, by using the multinomial regression approach. The model was as follows:
Logit (y=a*) = log p(y=a*) = β0 + β1 . Age + β2 . Gender + β3 . Race+ β4 . Marital Status +
1-p(y=a*)
β5 . Education + β6 . Employment Status + β7 . Income +
β8 . Overall Health Status + β9 . Comorbidities +
β10 . Number of comorbidities +
β11 . Antidepressant/Psychotherapy prescribed+ Ɛa
*-Depression frequency either not at all, several days or more than half the days (Reference –
Nearly every day), a-Error Term
All of the analyses were conducted first on individual therapy classes and later on
combinations of antidepressants. The analyses were conducted on a patient-level file obtained
by summarizing the scores from an events-level file. All the analyses were conducted at a
significance level of 0.05. The hypothesis tested in this analysis was that the QOL scores and
depression frequency would differ significantly across the groups. SAS v9.4 was used to
conduct the analyses and MS Excel 2016 was used for plotting graphs.
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Section 5.2: Results
Aim 3A: To compare the physical and mental component score (PCS/MCS) across
different classes in order to assess quality of life of cancer patients with comorbid
depression
Quality of life of patients was compared across different class of antidepressants/
psychotherapy and combinations of antidepressants using physical and mental component
scores (PCS and MCS). The mean PCS and MCS associated with each class are summarized in
Tables 16 and 17 respectively.
Table 16: Mean PCS across therapy class
Therapy class

Sample size

Mean PCS

Std Error of
95% CL for Mean
Mean
PCS
No therapy
9,480
38.58
0.2129
38.16
39.03
SSRI
3,404
41.18
0.4470
40.30
42.06
MA*
1,099
40.76
0.6899
39.39
42.13
SNRI
730
41.13
0.7769
39.44
42.82
TCA
224
38.68
1.0769
38.66
39.44
Psychotherapy
1,423
36.77
0.8525
35.72
37.93
Both**
1,271
35.87
0.8333
34.56
36.78
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
Both** - Antidepressant and psychotherapy
A higher score indicates a higher QOL
Table 17: Mean MCS across therapy class
Therapy class

Sample Size

Mean MCS

Std Error of
95% CL for Mean
Mean
MCS
No therapy
9,480
37.36
0.2126
36.94
37.77
SSRI
3,404
37.51
0.4195
36.69
38.34
MA*
1,099
36.76
0.6438
35.48
38.04
SNRI
730
38.16
0.7083
36.61
39.70
TCA
224
38.59
1.3822
36.81
39.42
Psychotherapy
1,423
31.64
0.8737
30.87
32.35
Both**
1,271
29.62
0.9095
27.21
31.34
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
Both** - Antidepressant and psychotherapy
A higher score indicates a higher QOL
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The above unadjusted analyses suggested that, a higher mean PCS was obtained with
SSRI, miscellaneous agents and SNRI. On comparing MCS, it was seen that a higher score was
associated with SNRI and TCA. The PCS scores associated with psychotherapy with or without
an antidepressant were even lower than no therapy at all. Similar results were obtained for mean
MCS scores, along with miscellaneous agents also having a score below no therapy at all. On
conducting unadjusted analyses using the ANOVA test, it was found that PCS and MCS for
some groups differed significantly from the others. These significant ANOVA results for PCS
and MCS are summarized in Appendix Figures 1 and 2 and Tables 5 and 6 respectively.
Adjusted regression analyses was conducted controlling for demographic factors, their health
status in general and comorbidities associated. These results are summarized in Tables 18 and
19.

Table 18: Regression results for PCS across depression therapy classes
Predictors

Estimate

Intercept*

23.728416

18-44 years
>65 years
45-65 years

3.874257
-1.815827
-

Males
Females

0.278189
-

Blacks
Asians
Multiple races
Whites

0.099802
1.559674
-0.069454
-

Widowed
Divorced
Separated
Never married
Married

-0.504700
-0.294626
1.250402
1.449368
-

Standard Error
0.93900531
Age Groups*
0.31629756
0.42259368
Gender
0.25408081
Race
0.33801221
1.01718881
0.59215191
Marital Status*
0.45096851
0.33787106
0.82722660
0.31241265
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t value

p-value

25.27

<.0001

11.78
-4.30
-

<.0001
<.0001
-

1.09
-

0.2742
-

0.30
1.53
-0.12
-

0.7679
0.1259
0.9067
-

-1.12
-0.87
1.51
4.64
-

0.2637
0.3837
0.1314
<.0001
-

Education
No education
1.373198
1.07486621
1.28
0.2021
School
0.408673
0.55035149
0.74
0.4582
High school
-0.228869
0.27561317
-0.83
0.4068
5+ years college
0.623551
0.44813450
1.39
0.1648
≤4 years college
Employment Status*
Employed
3.891197
0.32932964
11.82
<.0001
Unemployed
a
Income
Low
0.533477
0.36957637
1.44
0.1496
High
0.001782
0.37378312
0.01
0.9962
Middle class
Overall Health Status*
Excellent
27.793365
0.56299920
49.37
<.0001
Very good
25.297794
0.47079079
53.73
<.0001
Good
19.034358
0.42691104
44.59
<.0001
Fair
8.211462
0.43952025
18.68
<.0001
Poor
Comorbidities*
Asthma
-2.231539
0.44603500
-5.00
<.0001
Arthritis
-3.056831
0.34306491
-8.91
<.0001
Diabetes
1.611439
0.56801676
2.84
0.0048
High blood pressure
0.917330
0.44432410
2.06
0.0396
None
Number of Comorbidities
2
0.677611
1.05998349
0.64
0.5230
≥3
Antidepressant/Psychotherapy*
SSRI
2.297618
0.40744707
5.64
<.0001
MA**
2.243898
1.10656492
2.03
0.0432
SNRI
1.868457
0.62967328
2.97
0.0032
TCA
-0.280224
1.13371517
-0.25
0.8049
Psychotherapy
2.391769
1.34158557
1.78
0.0753
Both***
3.832430
1.54504948
2.48
0.0135
No therapy
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA** - Miscellaneous Agents
Both*** - Antidepressant and psychotherapy
*Significant predictors
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
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Table 19: Regression results for MCS across depression therapy classes
Predictors
Intercept*
18-44 years
>65 years
45-65 years
Males
Females
Blacks
Asians
Multiple races
Whites
Widowed
Divorced
Separated
Never married
Married
No education
School
High school
5+ years college
≤4 years college
Employed
Unemployed

Estimate
33.957960

Standard Error
1.43596729
Age Groups*
-2.067972
0.37344141
2.921289
0.54958779
Gender
-0.174395
0.35127254
Race
0.798348
0.46221061
-0.472144
1.27060925
0.732625
1.01384428
Marital Status*
-0.776112
0.63059156
-1.542013
0.43718346
-1.725167
0.89000522
-2.621354
0.43058545
Education
-0.450708
1.53321560
-0.138705
0.65117050
-0.103938
0.34966929
0.621971
0.58552212
Employment Status*
1.638000
0.41961254
-

Low
High
Middle class

-0.303451
0.853695
-

Excellent
Very good
Good
Fair
Poor

18.478604
14.931983
11.666374
6.477895
-

Asthma
Arthritis
Diabetes
High blood
pressure
None

0.434419
0.226897
1.673379
0.450593

Income a
0.50914415
0.50874153
Overall Health Status*
0.76617114
0.64048127
0.59302916
0.59607520
Comorbidities
0.52272693
0.42508743
0.75773470
0.65983624

-
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t value
23.65

p-value
<.0001

-5.54
5.32
-

<.0001
<.0001
-

-0.50
-

0.6198
-

1.73
-0.37
0.72
-

0.0849
0.7104
0.4703
-

-1.23
-3.53
-1.94
-6.09
-

0.2191
0.0005
0.0532
<.0001
-

-0.29
-0.21
-0.30
1.06
-

0.7689
0.8314
0.7664
0.2887
-

3.90
-

0.0001
-

-0.60
1.68
-

0.5515
0.0941
-

24.12
23.31
19.67
10.87
-

<.0001
<.0001
<.0001
<.0001
-

0.83
0.53
2.21
0.68

0.4064
0.5938
0.0278
0.4951

-

-

Number of Comorbidities
2
1.558807
0.16183439
9.63
0.7764
≥3
Antidepressant/Psychotherapy*
SSRI
-0.671898
0.57012753
-1.18
0.0259
MA**
-1.574317
1.08475602
-1.45
0.0036
SNRI
-3.037997
1.13809892
-2.67
0.0003
TCA
-2.064295
1.89204826
-1.09
0.3955
Psychotherapy
-0.409942
1.68289385
-0.24
0.2292
Both***
-1.178011
1.91372016
-0.62
0.0004
No therapy
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA** - Miscellaneous Agents
Both*** - Antidepressant and psychotherapy
*Significant predictors
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
The depression therapy class was significantly associated with PCS and MCS. It was
observed that except TCA, PCS was higher when any kind of antidepressant/ psychotherapy
was prescribed compared to no therapy. With MCS, it was observed that none of the
antidepressants/ psychotherapy led to an increase in MCS as compared to no therapy at all.
PCS and MCS were now compared across combinations of antidepressants identified
in aim 1A. The findings of mean PCS and MCS across these combinations are summarized in
Tables 20 and 21.
Table 20: Mean PCS across combination of antidepressants
Combinations
Sample size
Mean
Std Error of Mean 95% CL for Mean
SSRI-MA*
179
40.94
1.9131
37.18
44.70
SNRI-MA*
47
40.27
4.0428
32.32
48.22
SSRI-SNRI
42
44.25
3.2391
37.89
50.62
SSRI-TCA
34
37.52
2.6088
32.39
42.65
Other Combinations
16
42.27
5.84
30.31
53.62
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA*-Miscellaneous Agents
A higher score indicates a higher QOL
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Table 21: Mean MCS across combination of antidepressants
Combination of
Sample size
Mean
Std Error of 95% CL for Mean
antidepressants
Mean
SSRI-MA*
179
35.74
1.6074
32.58
38.90
SNRI-MA*
47
37.28
3.8294
29.75
44.81
SSRI-SNRI
42
36.25
2.7947
30.76
41.74
SSRI-TCA
34
40.65
2.7440
35.25
46.04
Other Combinations
16
32.89
5.51
22.52
43.35
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA*-Miscellaneous Agents
A higher score indicates a higher QOL
The findings suggest that, the PCS and MCS both were higher when antidepressants
were given in combination as compared to given individually. The mean PCS was highest when
SSRI was given in combination with SNRI, whereas the MCS was highest when SSRI was
given in combination with TCA. On comparing the PCS and MCS of those who were on
individual therapies to those who were using combinations of antidepressants, these mean scores
were significantly higher for those who were on combinations of antidepressants at a p-value of
0.0352 and 0.0417 for PCS and MCS respectively. Quality of life, when measured using PCS
and MCS was higher when SSRI was given in combination with either SNRI or TCA. However,
the differences in PCS and MCS were not significant in unadjusted analyses conducted using
the ANOVA test. Adjusted analyses was carried similarly for combinations and the results
obtained suggested that, PCS increased with all the combinations as compared to getting no
combination prescribed, the maximum increase in PCS was when SSRI was prescribed with a
miscellaneous agent (estimate=2.47, p-value=0.0182). MCS increases only when SSRI-TCA
(estimate=2.2, p-value=0.45) was the combination prescribed as compared to getting no
combination prescribed. The combination of antidepressants was significantly associated with
the PCS whereas it was associated with the MCS at the significance level of 0.1. These
regression results are summarized in Appendix Tables 7 and 8.
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Aim 3B: To compare Patient Health Questionnaire – 2 (PHQ-2) scores and the frequency
of depression obtained from Short Form version 12 (SF-12) to assess quality of life of
cancer patients with comorbid depression
In order to compare quality of life of patients across classes of antidepressants and
psychotherapy, PHQ-2 scores and a categorical variable indicating depression frequency from
the SF version 12 were used. Mean PHQ-2 scores across the depression therapy classes and
proportions of patients belonging to each category of depression frequency across the classes
are summarized in Figure 11. SSRI were associated with the lowest PHQ-2 scores (mean =
1.7826) indicating lesser tendency towards depression. The frequency of feeling depressed was
the lowest with SSRI too (highest percentage of patients reporting “Not at all” – 42%). Patients
receiving antidepressant and psychotherapy both had the highest PHQ-2 scores (mean = 2.29)
and highest percentage (17.94%) of patients reporting “Nearly every day” for depression
frequency. These findings thus suggest that, the highest quality of life and lowest tendency
towards depression is associated with SSRI and the highest tendency towards depression when
antidepressant is given along with psychotherapy. These unadjusted findings are summarized in
figure 11. On conducting ANOVA test for PHQ-2 scores, SSRI scores differed significantly
from psychotherapy and no therapy both. These significant results are summarized in Appendix
Figure 3 and Appendix Table 9. Unadjusted analyses carried out for depression frequency using
chi square was significant at a p-value of 0.0056. Adjusted regression analyses was thus
conducted on PHQ scores (surveyreg), these results are summarized in Table 22, and depression
frequency (multinomial logistic regression) these results are summarized in Table 23.
Multinomial logistic regression was conducted using “3: Nearly every day” as the reference
group for the outcome variable.

70

Depression Frequency by Therapy Class
45
40
35
30
25
20
15
10
5
0
SSRI

MA*
Not at all

SNRI
Several Days

TCA
More than half the days

Psychotherapy

Both

Nearly every day

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
Both – Antidepressants and Psychotherapy
A higher PHQ-2 score indicates higher tendency towards depression
Figure 11 – Mean PHQ-2 scores and depression frequency across therapy class
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Table 22: Regression results for PHQ-2 scores across depression therapy classes
Parameter
Intercept*

Estimate

Standard Error

t Value

Pr > |t|

3.8262809

0.42733705

8.95

<.0001

Age Groups*
18-44 years

0.1758891

0.05330577

3.30

0.0011

>65 years

-0.2965855

0.08613440

-3.44

0.0006

-

-

-

-

0.1137426

0.04907728

2.32

0.0209

-

-

-

-

45-65 years

Gender*
Males
Females

Race
Blacks

-0.0171856

0.07168833

-0.24

0.8107

Asians

-0.0236067

0.14913997

-0.16

0.8743

Multiple races

0.0815454

0.16004197

0.51

0.6107

-

-

-

-

Whites

Marital Status*
Widowed

0.1488145

0.09208217

1.62

0.1068

Divorced

0.2530129

0.06095075

4.15

<.0001

Separated

0.2978353

0.12228318

2.44

0.0153

Never married

0.2739648

0.06652892

4.12

<.0001

-

-

-

-

Married

Education*
No education

-0.1088568

0.29883598

-0.36

0.7158

School

0.1389425

0.11449242

1.21

0.2256

High school

0.1137930

0.05271159

2.16

0.0314

5+ years college

-0.1395697

0.08117844

-1.72

0.0863

≤4 years college

-

-

-

-

Employment Status*
Employed
Unemployed

-0.3578200

0.06237240

-5.74

<.0001

-

-

-

-
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Income a*
Low

0.1865571

0.07900060

2.36

0.0187

High

-0.1139192

0.06636350

-1.72

0.0868

-

-

-

-

Middle class

Overall Health Status*
Excellent

-3.1065494

0.11563765

-26.86

<.0001

Very good

-2.7051892

0.10574756

-25.58

<.0001

Good

-2.1801921

0.09885237

-22.06

<.0001

Fair

-1.2064063

0.10037303

-12.02

<.0001

Poor

-

-

-

-

Comorbidities
Asthma

-0.0654268

0.08188706

-0.80

0.4247

Arthritis

0.0802863

0.06562501

1.22

0.2219

Diabetes

-0.1317421

0.11799824

-1.12

0.2649

High blood pressure

0.0221986

0.08542314

0.26

0.7951

-

-

-

-

None

Number of Comorbidities
2
≥3

0.0043501

0.21438471

0.02

0.9838

-

-

-

-

Antidepressant/Psychotherapy*
SSRI

-0.0103671

0.05130837

-0.20

0.8400

MA**

0.2050913

0.10252836

2.00

0.0461

SNRI

0.3253804

0.11778651

2.76

0.0060

TCA

-0.0988881

0.18589890

-0.53

0.5950

Psychotherapy

0.1499525

0.16325672

0.92

0.3589

Both***

0.2697418

0.24444909

1.10

0.2705

-

-

-

-

No therapy

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA** - Miscellaneous Agents
Both*** - Antidepressant and psychotherapy
*Significant predictors
a
- Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
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Thus, as seen from the adjusted regression results, the depression therapy class was
significantly associated with the PHQ-2 scores at the significance level of 0.05. The PHQ-2
scores were lower with the utilization of SSRI and TCA as compared to no therapy at all. The
adjusted results were consistent for SSRI with unadjusted analyses where the mean PHQ-2 score
for SSRI was lower than no therapy at all.
Table 23: Multinomial regression results for depression frequency
Predictor

18-44 years
> 65 years
45-65 years
Males
Females

Depression frequency (OR, Confidence Intervals)a
0: Not at all
1: Several Days
2: More Than Half
the Days
Age**
0.686**
0.851
1.116
(0.540, 0.871)
(0.664, 1.092)
(0.864, 1.443)
1.845**
1.297
1.170
(1.269, 2.682)
(0.910, 1.848)
(0.778, 1.759)
Reference
Reference
Reference
Gender
0.712
(0.505, 1.003)
Reference

0.741
(0.520, 1.055)
Reference

0.948
(0.640, 1.420)
Reference

0.957
(0.527,1.736)
1.110
(0.309,3.989)
1.308
(0.425,4.019)
Reference

2.291**
(1.364,3.847)
1.158
(0.291,4.613)
2.870
(0.896,9.190)
Reference

Marital Status**
0.478**
0.420**
(0.244,0.939)
(0.220,0.804)
0.513**
0.529**
(0.321,0.819)
(0.339,0.827)
0.400
0.725
(0.152,1.052)
(0.315,1.667)
0.535**
0.693
(0.331,0.867)
(0.420,1.144)
Reference
Reference

0.657
(0.287,1.503)
0.879
(0.519,1.491)
0.775
(0.294,2.044)
1.188
(0.174,4.029)
Reference

Race
Blacks
Asians
Multiple Races
Whites

Widowed
Divorced
Separated
Never Married
Married

0.985
(0.554,1.752)
1.774
(0.572,5.500)
2.120
(0.647,6.948)
Reference
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No education
Elem/ Mid School
High school
5+ Years College
≤ 4 years college

Employed
Unemployed

Low income
High income
Middle class income

Excellent
Very good
Good
Fair
Poor

Asthma
Arthritis
Diabetes
High blood pressure
None

2
≥3

Education
0.836
(0.174,4.029)
0.819
(0.358,1.876)
0.831
(0.558,1.239)
1.206
(0.576,2.526)
Reference

0.604
(0.098,3.700)
0.695
(0.333,1.450)
0.698
(0.485,1.005)
1.048
(0.504,2.180)
Reference

1.050
(0.082,13.420)
1.321
(0.603,2.893)
0.972
(0.625,1.510)
0.965
(0.404,2.308)
Reference

Employment Status**
1.959**
1.793**
(1.255, 3.060)
(1.144, 2812)
Reference
Reference

1.816**
(1.102, 2.993)
Reference

Income b**
0.716**
0.750**
(0.535, 0.958)
(0.575, 0.978)
1.176
1.009
(0.806, 1.715))
(0.689, 1.478)
Reference
Reference

0.936
(0.711, 1.233)
0.965
(0.620, 1.501)
Reference

Overall Health Status**
228.761**
28.251**
(68.720, 761.51)
(8.520, 93.683)
101.589**
24.818**
(45.245, 228.098)
(11.797, 52.210)
24.931**
10.740**
(12.851, 48.365)
(6.001, 19.22)
4.562**
4.316**
(2.407, 8.649)
(2.491, 7.479)
Reference
Reference

4.842**
(1.179, 19.894)
5.649**
(2.577, 12.385)
2.670**
(1.493, 4.77)
1.949**
(1.118, 3.396)
Reference

Comorbidities
0.810
0.708
(0.477, 1.374)
(0.410, 1.223)
1.206
0.971
(0.721, 2.018)
(0.597,1.577)
2.709
1.655
(0.162, 6.314)
(0.737, 3.718)
1.031
0.765
(0.544, 1.953)
(0.391, 1.498)
Reference
Reference

0.552
(0.279, 1.092)
0.871
(0.490, 1.549)
1.705
(0.636, 4.572)
0.899
(0.423, 1.912)
Reference

Number of Comorbidities
0.244
0.221
(0.041, 1.468)
(0.049, 1.003)
Reference
Reference

0.182
(0.029, 1.133)
Reference
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SSRI
MA*
SNRI
TCA
Psychotherapy
Both***

Antidepressant/ Psychotherapy
2.318
0.752
(0.654, 8.224)
(0.236, 2.399)
1.547
0.688
(0.403, 5.935)
(0.204, 2.321)
1.371
0.596
(0.350, 5.371)
(0.168, 2.107)
2.365
0.695
(0.507, 11.044)
(0.163, 2.969)
1.580
0.774
(0.368, 6.788)
(0.210, 2.847)
Reference
Reference

1.824
(0.532, 6.257)
1.641
(0.439, 6.129)
1.758
(0.431, 7.161)
1.568
(0.371, 6.618)
1.122
(0.273, 4.605)
Reference

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
*MA = Miscellaneous Agents
a
The reference class for depression frequency was 3: Nearly every day
** - Significant results
Both*** - Antidepressant and Psychotherapy
b
- Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)

Thus, as seen from the multinomial regression results, on adjusting for other factors,
antidepressant/ psychotherapy class was not significantly associated with the frequency of
depression. However, numerically it was found that, as compared to both the therapies
(antidepressant and psychotherapy) being prescribed, all the classes had a higher likelihood of
reporting either “not at all” or “more than half days” of depression (OR>1).
Mean PHQ-2 scores and depression frequency were then compared across combinations
of antidepressants, since, PCS and MCS suggested that a better quality of life was associated
with combinations. SSRI with SNRI was the combination associated with the lowest PHQ-2
scores (mean = 1.13) indicating lesser tendency towards depression. The findings of
significantly lower PHQ-2 scores (p-value = 0.0214) being associated with combinations of
antidepressants as compared to individual classes were consistent with the results suggested by
PCS and MCS. The frequency of feeling depressed was the lowest with SSRI and TCA as a
combination (highest percentage of patients reporting “Not at all” – 46.87%) with SSRI-SNRI
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combination having the lowest percentage (8.10%) of patients reporting “Nearly every day”
depression. These findings thus suggest that, the highest quality of life and lowest tendency
towards depression is associated with SSRI – SNRI or SSRI - TCA. These unadjusted findings
are reported in Figure 12. ANOVA results for unadjusted analyses suggested that the differences
in PHQ-2 scores across the combination groups were not significant. Chi-square test for
depression frequency could not be conducted since one of the categories had a sample size of
less than 5, hence Fisher’s exact test was conducted which suggested that, the depression therapy
class was not significantly associated with the depression frequency (p-value=0.713).

77

Depression frequency by combinaitons of antidepressants
70
60
50
40
30
20
10
0
SSRI-MA*

SNRI-MA*
Not at all

Several Days

SSRI-SNRI
More than half the days

SSRI-TCA

Other Combinations

Nearly every day

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
Both – Antidepressants and Psychotherapy
A higher PHQ-2 score indicates higher tendency towards depression
Figure 12 – Mean PHQ-2 scores and depression frequency across combinations of
antidepressants
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Adjusted analyses was then conducted to evaluate if the combinations of antidepressants were
associated with PHQ-2 scores (surveyreg) or depression frequency (multinomial logistic
regression) on accounting for other factors. Results for these are summarized under Appendix
Tables 10 and 11 respectively. On controlling for other factors, the combinations of
antidepressant were not significantly associated with the PHQ-2 score at a p-value of 0.7665.
Numerically, all the combinations except SNRI - Miscellaneous Agents (estimate = 0.5534, pvalue = 0.2659) and SSRI-SNRI (estimate = 0.0905, p-value = 0.8032) reduced PHQ-2 scores
as compared to not getting any combination of antidepressant prescribed. The combinations
were however significantly associated with the depression frequency on controlling for other
factors. Patients receiving ‘other combinations’ (TCA either with a miscellaneous agent or
SNRI) were less likely to report more than half days of depression as compared to no
combinations prescribed.
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Section 5.3: Discussion
The study thus suggested that individually SSRI, miscellaneous agents and SNRI were
associated with a higher mean PCS whereas SNRI and TCA were associated with a higher mean
MCS. Psychotherapy with or without an antidepressant was associated with lower scores. These
findings were consistent with the study findings in the literature that suggested pharmacotherapy
had higher effectiveness than psychotherapy. A study conducted by Siddique et al. suggested
that amongst depressed women with moderate baseline depression, pharmacotherapy was
superior to psychotherapy.54 In women with severe depression, psychotherapy was superior,
however after 12 months. This study was however not restricted to cancer population, also, the
psychotherapy that they looked at was cognitive-behavioral therapy or community mental health
service and not necessarily an office-based physician visit.54 A study conducted by Vyas et al.
suggested that amongst cancer patients with depression, the mean MCS score was lowest among
those who received psychotherapy with or without antidepressants compared to those receiving
antidepressants only and those with no reported use of either.30 Similar results were replicated
in our study. The study conducted by Vyas et al. however, did not look at classes of
antidepressants or combinations of antidepressants separately. Adjusted regression analyses in
our study suggested that, PCS was higher with any kind of antidepressant/psychotherapy except
TCA compared to no treatment at all. MCS however was not higher for any of therapy classes
as compared to no treatment at all. It was also found that PCS and MCS both were even higher
when the antidepressants were used in combination with each other, with SSRI-SNRI producing
the highest PCS and SSRI-TCA producing the highest MCS. It was thus suggested that, using
SSRI either in combination with SNRI or TCA or individually produced the highest quality of
life. The results of SSRI being associated with a higher QOL were consistent with a study that
compared pharmacotherapy involved in treating depression. However, this study did not include
psychotherapy and only included monotherapy, excluding combinations of antidepressants. The
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study was also not restricted to cancer population.55 There have been studies comparing the
effectiveness and suggesting that pharmacotherapy is more effective than psychotherapy.55,56
These were however, not necessarily amongst cancer patients55 or necessarily did not look at
quality of life as an outcome measure for effectiveness.56
On comparing the PHQ-2 scores and depression frequency from SF-12, it was observed
that, SSRI had the lowest PHQ-2 score indicating lesser tendency towards depression, the
depression frequency was also reported to be low by maximum patients in the SSRI group. In
addition, combinations of antidepressants had even lower PHQ-2 scores, with SSRI-SNRI
having the lowest score. The frequency of depression was reported to be low with most of the
patients in the SSRI-TCA group. Thus, similar results were obtained for quality of life by both
these methods, where SSRI was suggested to be superior to others, individually or in
combination with either an SNRI or a TCA. These findings were consistent with the literature,
where a study conducted by Mills et al. suggested that the PHQ scores and depression frequency
improved after antidepressant initiation.57 However, in this study, antidepressants were not
compared against psychotherapy. In addition, this study was not restricted to cancer patients.
The results of SSRI being associated with the highest QOL and relatively lower prescription
and office-based visit costs (from specific aim 2) also align with the results of a study that has
already been conducted which suggests that a lower financial burden usually leads to a higher
QOL and lower tendency towards depression.6
In addition to the limitations stated above, there were certain QOL limitations identified.
One of the major limitation of the study is selection bias. The reason for lower MCS with the
treatment groups or the lower PCS/MCS and higher PHQ-2 scores with psychotherapy could be
due to the difference in population across classes of antidepressants and the baseline scores
being worse to begin with as compared to others. Presence of such selection bias affects the
validity of the results obtained above. Secondly, quality of life is a subjective term and the
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scores/frequency of depression could vary based on personal preferences. Thirdly, the quality
of life could be associated with the cancer condition and not depression, which is a common
limitation of studies looking at comorbidities. However certain cancer characteristics such as,
the type of cancer, remission state and other comorbidities associated were looked at in the study
which would help in reducing the bias but due to maximum missing values this effect would be
minimum. Certain types of cancers have higher survival rates and depression levels in these
patients could be different as compared to those with lower survival rates.58 Also, some cancers
have certain effects on the endocrine and hormonal system which would present depression
differently in these.59 Due to the missing values, these effects of type of cancer could not be
studied. Moreover, the data being cross-sectional, it was not possible to track the patients.
Depression treatment could have long-term effects and could improve quality of life after a long
duration; however, this could not be tracked due to data limitations and the study being crosssectional. In addition, certain antidepressants were reported to have interactions with certain
chemotherapeutic drugs which could lower the quality of life of certain specific cancer patients
mainly breast cancer patients.60 However, this could not be tracked because of the lack of
available data. Finally, the stage of cancer could also have some effect on the quality of life;
however, this is not captured by MEPS and hence was not controlled for in the study.
Despite of these limitations, the findings add a lot to the literature. None of the studies
so far have looked at quality of life associated with separate classes of antidepressants or
combinations of antidepressants. Studies so far have compared antidepressants as a whole with
psychotherapy or no treatment at all; however, none of them have looked at individual classes.
This is the first study that also compares the quality of life associated with combinations of
antidepressants and suggests that higher quality of life scores are associated with combinations
of antidepressants as compared to using antidepressants individually. These findings form the
basis for future studies to explore the combinations even further, since these were associated
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with a higher QOL. However, a higher QOL could also be associated with higher side effects
which could be explored in future studies. As stated above, our study has limitations due to
selection bias involved, future studies could address this limitation by using a longitudinal
dataset or matching the patients and produce more robust findings. Our study is hypothesis
generating for such future studies. On achieving more robust results, the patient-reported QOL
findings could also provide certain guidance to clinicians to manage depression amongst cancer
patients more efficiently.
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CHAPTER VI: CONCLUSIONS AND FUTURE RESEARCH
Section 6.1: Conclusions
Our study examined the patterns of use, sociodemographic characteristics, prescription
medicine costs, office-based visit costs and QOL associated with the utilization of
antidepressants and psychotherapy amongst cancer patients with a comorbid depression
condition. These factors were studied across all the classes of antidepressants/ psychotherapy
and were compared against each other. It was found that in a majority of patients had untreated
depression (53.64%). Amongst those receiving antidepressants, SSRI was the most commonly
prescribed antidepressant with or without psychotherapy. Psychotherapy was also prescribed to
many patients with or without any antidepressant. The patterns of use were similar across all
the classes of antidepressants. As suggested by the trends observed throughout the study period,
the use of psychotherapy and miscellaneous agents has eventually increased with SSRI still
being the most frequently prescribed antidepressant class. On identifying the sociodemographic
characteristics, age, employment status and education were found to be the most significantly
associated predictors of receiving any particular class of antidepressant/psychotherapy. Age and
employment status were significant even in most of the adjusted analyses, where people below
65 years of age and who were employed had a higher PCS and a lower PHQ score. MCS was
however higher in those above 65 years of age and employed. These were not significantly
associated with total prescription medicine or office-based visit costs.
Comparing the total prescription medicine and office-based visit costs, it was found that,
the adjusted mean prescription costs per purchase were the highest for SNRI ($112.92 per
fill/purchase) with out of pocket and private insurance being the sources of payments in majority
of the patients. The adjusted office-based visit costs mainly associated with psychotherapy were
the highest for those receiving psychotherapy only without any antidepressant (mean =
$166.39/visit). The sources of payment were similar to those of prescription medicine costs.
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Some other major office-based visits identified along with psychotherapy were general checkup,
treatment and follow-up visit.
Quality of Life as measured by PCS was the highest for SSRI (mean = 41.18), whereas
MCS was the highest for TCA (mean = 38.59). Psychotherapy with or without any
antidepressants was associated with a lower PCS and MCS. Both the PCS and MCS were higher
when the antidepressants were prescribed in combination with one another, with SSRI-SNRI
associated with the highest PCS (mean = 44.25) and SSRI-TCA associated with the highest
MCS (mean = 40.65). The PHQ-2 scores and depression frequency also suggested using
antidepressants in combinations. SSRI-SNRI was associated with the lowest PHQ-2 score
(mean = 1.13) indicating a lower tendency towards depression. It was thus suggested that the
QOL was the highest when SSRI was given in combination with either SNRI or TCA by all the
measures. As mentioned above, these results could however involve selection bias since the
groups were not randomized and were non uniform.
As stated above, these results would further help policy makers and clinicians in guiding
their decision regarding depression management amongst cancer patients. It also provides a
framework for further studies to be conducted which could explore the outcomes associated
with SSRI more, since as identified in this study, it is associated with a lower cost and higher
QOL. Finally, it is one of the first studies looking at patterns of use, costs and QOL across
classes of antidepressants/ psychotherapy amongst cancer patients with depression in the US in
a nationally representative population and hence has high generalizability.
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Section 6.2: Future Research
Based on the results obtained in our study, further hypotheses can be generated in order
to carry out a cost-effective or a cost-benefit analysis study comparing antidepressant (identified
in our study that they have higher costs and higher QOL) to psychotherapy. The current study
was cross-sectional and there were certain other data limitations to it as mentioned above, which
can be overcome by using a longitudinal database like SEER. Family history of depression was
identified as one of the predictors for antidepressant use by a study.18 This could not be studied
using MEPS due to data limitation but can be explored further using another dataset or
conducting a primary research study. In addition, costs/outcomes associated with combinations
of antidepressants can be explored further, since as suggested by this research, they are
associated with a higher QOL. Although, combinations of antidepressants could also be
associated with higher side effects resulting into higher hospital visits and utilization, which
could also be studied further. Since, antidepressants can have long-term effects, future studies,
with the help of an appropriate dataset or by collecting data primarily can look at some of the
long-term effects and costs associated with these.
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APPENDIX
Table 1: Names of antidepressants under each class included by MEPS
Class of Antidepressant

Specific Names

SSRI

Fluoxetine, Paroxetine, Citalopram, Escitalopram, Sertraline

MA*

Bupropion, Vilazodone, Trazodone

SNRI

Duloxetine, Venlafaxine, Milnacipran

TCA

Amitriptyline, Imipramine, Desipramine, Clomipramine,
Doxepin

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA* - Miscellaneous Agents
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Table 2: Regression results for out of pocket mean
Parameter

Estimate

Standard Error

t Value

Pr > |t|

Intercept*

24.89205222

8.74675731

2.85

0.0044

Age Groups
18-44 years

-1.50047886

1.30243726

-1.15

0.2493

> 65 years

1.00642186

1.77273562

0.57

0.5702

45-65 years

-

-

-

-

2.09221651

1.18641357

1.76

0.0779

-

-

-

-

Gender
Males
Females

Race*
Blacks

-5.00697489

1.62160864

-3.09

0.0020

Asians

-10.01955001

4.83803174

-2.07

0.0384

Multiple Races

-6.01595753

3.40774864

-1.77

0.0775

-

-

-

-

Whites

Marital Status
Widowed

3.24869167

2.07868341

1.56

0.1181

Divorced

-1.17190603

1.45237018

-0.81

0.4198

Separated

-0.97394564

2.68520613

-0.36

0.7168

Never married

-0.40774070

1.50994369

-0.27

0.7871

-

-

-

-

Married

Education
No education

-1.43296923

7.49235072

-0.19

0.8483

Elem/ Mid School

-4.67678411

2.13444176

-2.19

0.0285

High school

-3.00020914

1.22495556

-2.45

0.0143

5+ years college

-0.64547227

2.20276081

-0.29

0.7695

≤4 years college

-

-

-

-

Employment Status*
Employed
Unemployed

1.17311514

1.36332519

3.06

0.0022

-

-

-

-
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Incomea
Low

2.24144739

1.72693686

1.30

0.1944

High

1.40480556

1.74631474

0.80

0.4212

-

-

-

-

Middle class

Overall Health Status
Excellent

-3.91695499

2.91685784

-0.66

0.5111

Very good

-1.01249562

2.19795533

-0.46

0.6451

Good

-1.76607286

2.00820408

-0.38

0.7029

Fair

-1.95592030

1.99388251

-0.98

0.3266

Poor

-

-

-

-

Comorbidities*
Asthma

-3.93870068

1.82370555

-2.16

0.0308

Arthritis

-7.49776796

1.39887361

-5.36

<.0001

Diabetes

-5.92353195

3.00399085

-1.97

0.0487

High blood pressure

-5.98537545

2.01492051

-2.97

0.0030

-

-

-

-

None

Number of Comorbidities
2
≥3

13.12443039

4.62407154

0.68

0.4993

-

-

-

-

Antidepressant/ Psychotherapy*
SSRI

3.56660851

7.03681896

0.51

0.6123

MA**

-1.76813682

7.29705630

-0.11

0.9162

SNRI

10.44893516

7.34510560

1.42

0.01549

TCA

-9.41596457

8.23746390

-0.78

0.04361

Both***
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA** - Miscellaneous Agents
Both*** - Antidepressant and psychotherapy
*Significant predictors
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)

97

Table 3: Regression results for private insurance mean

Parameter
Intercept*

Estimate

Standard Error

t Value

Pr > |t|

6.92742626

15.34217368

0.45

0.6516

Age Groups*
18-44 years

-10.69437442

2.28452877

-4.68

<.0001

> 65 years

-13.09469435

3.10945151

-4.21

<.0001

45-65 years

-

-

-

-

Gender*
Males
Females

-2.05571531

2.08101841

-0.99

0.03233

-

-

-

-

Race
Blacks

-1.40114029

2.84436855

-0.49

0.6223

Asians

-4.26155647

8.48610755

-0.50

0.6156

Multiple Races

-5.24204676

5.97733190

-0.88

0.3805

-

-

-

-

Whites

Marital Status*
Widowed

-9.99602554

3.64609658

-2.74

0.0061

Divorced

-18.60734786

2.54751730

-7.30

<.0001

Separated

-10.89525996

4.70996249

-2.31

0.0207

Never married

-11.06275973

2.64850362

-4.18

<.0001

-

-

-

-

Married

Education*
No education

-16.51308617

13.14189269

-1.26

0.2090

School

-14.22990611

3.74389902

-3.80

0.0001

High school

-3.88944507

2.14862266

-1.81

0.0703

5+ years college

4.55515847

3.86373346

1.18

0.2385

≤4 years college

-

-

-

-

Employment Status*
Employed
Unemployed

-10.52912219

2.39132871

-5.24

<.0001

-

-

-

-
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Incomea*
Low

0.03531818

3.02911860

0.01

0.9907

High

12.75315004

3.06310819

4.16

<.0001

-

-

Middle class

Overall Health Status*

Excellent

3.57859162

5.11628916

0.70

0.4843

Very good

-4.53679795

3.85530444

-1.95

0.0506

Good

9.06168072

3.52247292

1.15

0.02489

Fair

7.35823912

3.49735230

0.39

0.6978

Poor

-

-

-

Comorbidities
Asthma

1.52376768

3.19885487

0.16

0.8699

Arthritis

-3.48482396

2.45368210

-0.20

0.8434

Diabetes

-19.48482396

5.26912405

-0.19

0.8434

High blood pressure

-3.33090645

3.53425381

-0.94

0.3460

-

-

0.88

0.3809

-

-

None

Number of Comorbidities

2
≥3

13.10729660

8.11081251

Antidepressant/Psychotherapy*

SSRI

31.40857817

12.34287116

1.41

0.01585

MA**

36.42555682

16.42555682

1.28

0.01994

SNRI

54.34920142

12.88361866

2.67

0.0077

TCA

5.15450675

14.44885198

0.36

0.7213

-

-

Both***

-

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA** - Miscellaneous Agents
Both*** - Antidepressant and psychotherapy
*Significant predictors
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
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Table 4: Regression results for total mean costs associated with office-based visits across
the depression therapy classes

Parameter
Intercept

Estimate

Standard Error

t Value

Pr > |t|

53.6476569

187.3324928

0.29

0.7747

Age groups
18-44 years

-1.9655426

22.2586973

-0.09

0.9297

> 65 years

-17.5375943

47.5225233

-0.37

0.7122

45-65 years

-

-

-

-

11.8761283

20.6516483

0.58

0.5655

-

-

-

-

Gender
Males
Females

Race
Blacks

26.7029490

28.7576662

0.93

0.3535

Asians

-29.5338169

94.3807429

-0.31

0.7544

Multiple Races

29.9604617

64.3155627

0.47

0.6415

-

-

-

-

Whites

Marital Status
Widowed

-45.9267711

50.7617867

-0.90

0.3659

Divorced

-26.7392134

26.5802324

-1.01

0.3148

Separated

-38.5364169

46.1481697

-0.84

0.4040

Never married

-3.6898327

25.4342062

-0.15

0.8847

-

-

-

-

348.5230548

126.7031474

2.75

0.0061

School

-1.2809766

48.4710790

-0.03

0.9789

High school

-7.9406433

22.1071736

-0.36

0.7196

5+ years college

79.3119381

36.6317060

2.17

0.0308

≤4 years college

-

-

-

-

Married

Education*
No education

Employment Status
Employed
Unemployed

31.5660583

23.7834408

1.33

0.1849

-

-

-

-

100

Income a
Low

2.3544166

29.9792873

0.08

0.9374

High

-18.1456907

31.2543869

-0.58

0.5617

-

-

-

-

Middle class

Overall Health Status
Excellent

-30.1133732

52.4238654

-0.57

0.5659

Very good

-2.0131863

42.3824247

-0.05

0.9621

Good

-17.1224176

40.0574044

-0.43

0.6692

Fair

-17.4989455

39.4296601

-0.44

0.6573

Poor

-

-

-

-

Comorbidities
Asthma

-3.5462970

30.7966528

-0.12

0.9084

Arthritis

-26.0213489

29.3743990

-0.89

0.3760

Diabetes

-0.1337772

62.6870647

-0.00

0.9983

High blood
pressure

42.1564507

37.0422598

1.14

0.2555

-

-

-

-

None

Number of comorbidities
2
≥3

72.8539973

175.3242383

0.42

0.6779

-

-

-

-

Antidepressant along with psychotherapy
SSRI

-54.7345382

22.8998066

-2.39

0.0171

MA**

-25.2182136

30.4261791

-0.83

0.4075

SNRI

-11.4613521

35.3772990

-0.32

0.7461

TCA

-0.9686245

73.6722672

-0.01

0.9895

-

-

-

-

Psychotherapy
alone

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA** - Miscellaneous Agents
*Significant predictors
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
No t – No therapy
MA* - Miscellaneous Agents
Both- Antidepressant and Psychotherapy both
Figure 1: Distribution of PCS across depression therapy classes
Table 5 – Significant ANOVA results for PCS comparison across depression therapy
classes
Comparisons significant at the 0.05 level are indicated by ***.
Therapy class

Difference Between
Means

Simultaneous 95% Confidence
Limits

3: SNRI - 0: No t a

3.6162

1.2188

6.0137

***

3: SNRI - 5: Psyc

6.6499

2.9946

10.3051

***

3: SNRI - 6: Both b

6.9709

0.7615

13.1803

***

1: SSRI - 0: No t

2.8004

1.6221

3.9786

***

1: SSRI - 5: Psyc

5.8340

2.8338

8.8342

***

1: SSRI - 6: Both

6.1550

0.3072

12.0028

***

2: TCA - 0: No t

2.1614

0.0380

4.2847

***
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2: TCA - 5: Psyc

5.1950

1.7134

8.6766

***

0: No t - 3: SNRI

-3.6162

-6.0137

-1.2188

***

0: No t - 1: SSRI

-2.8004

-3.9786

-1.6221

***

0: No t - 2: TCA

-2.1614

-4.2847

-0.0380

***

0: No t - 5: Psyc

3.0336

0.1603

5.9069

***

5: Psyc - 3: SNRI

-6.6499

-10.3051

-2.9946

***

5: Psyc - 1: SSRI

-5.8340

-8.8342

-2.8338

***

5: Psyc - 2: TCA

-5.1950

-8.6766

-1.7134

***

5: Psyc - 0: No t

-3.0336

-5.9069

-0.1603

***

6: Both - 3: SNRI

-6.9709

-13.1803

-0.7615

***

6: Both - 1: SSRI
-6.1550
-12.0028
-0.3072
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
a-No therapy
b-Antidepressant and Psychotherapy Both

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
No t – No therapy
MA* - Miscellaneous Agents
Both- Antidepressant and Psychotherapy both
Figure 2: Distribution of MCS across depression therapy classes
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Table 6 – Significant ANOVA results for MCS comparison across depression therapy
classes
Comparisons significant at the 0.05 level are indicated by ***.
Therapy Class

Difference
Between
Means

Simultaneous 95% Confidence
Limits

3: SNRI - 5: Psyc

8.1075

4.6311

11.5839

***

3: SNRI - 6: Both a

8.9740

3.0684

14.8795

***

4: TCA - 5: Psyc

7.9680

2.9894

12.9466

***

4: TCA - 6: Both

8.8345

1.9369

15.7320

***

1: SSRI - 5: Psyc

6.3814

3.5280

9.2349

***

1: SSRI - 6: Both

7.2479

1.6862

12.8096

***

0: No t b - 5: Psyc

6.3029

3.5702

9.0356

***

0: No t - 6: Both

7.1694

1.6686

12.6701

***

2: MA* - 5: Psyc

5.6476

2.3364

8.9589

***

2: MA* - 6: Both

6.5141

0.7042

12.3239

***

5: Psyc - 3: SNRI

-8.1075

-11.5839

-4.6311

***

5: Psyc - 4: TCA

-7.9680

-12.9466

-2.9894

***

5: Psyc - 1: SSRI

-6.3814

-9.2349

-3.5280

***

5: Psyc - 0: No t

-6.3029

-9.0356

-3.5702

***

5: Psyc - 2: MA*

-5.6476

-8.9589

-2.3364

***

6: Both - 3: SNRI

-8.9740

-14.8795

-3.0684

***

6: Both - 4: TCA

-8.8345

-15.7320

-1.9369

***

6: Both - 1: SSRI

-7.2479

-12.8096

-1.6862

***

6: Both - 0: No t

-7.1694

-12.6701

-1.6686

***

6: Both - 2: MA*

-6.5141

-12.3239

-0.7042

***

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
a- Antidepressant and Psychotherapy Both
b-No therapy
MA* - Miscellaneous Agents
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Table 7: Regression results for Physical Component Scores for combinations of
antidepressants
Parameter
Intercept*

Estimate

Standard Error

t Value

Pr > |t|

23.737071

0.93949108

25.27

<.0001

Age groups*
18-44 years

3.544700

0.32190941

11.01

<.0001

> 65 years

-1.531427

0.41001011

-3.74

0.0002

45-65 years

-

-

-

-

0.327339

0.25427629

1.29

0.1987

-

-

-

-

Gender
Males
Females

Race
Blacks

-0.073475

0.33992723

-0.22

0.8290

Asians

1.399997

1.02685030

1.36

0.1735

Multiple Races

-0.087833

0.57709360

-0.15

0.8791

-

-

-

-

Whites

Marital Status*
Widowed

-0.526873

0.44996723

-1.17

0.2423

Divorced

-0.305923

0.33941

-0.9

0.3679

Separated

1.25079

0.83265

1.5

0.1338

Never married

1.43798

0.31128

4.62

<.0001

-

-

-

-

Married

Education
No education

1.14764

1.05989

1.08

0.2795

Elem/ Mid School

0.30336

0.54825

0.55

0.5803

High school

-0.2583

0.27664

-0.93

0.351

5+ years college

0.64182

0.44502

1.44

0.15

≤4 years college

-

-

-

-

Employment Status*
Employed
Unemployed

3.950119

0.32796056

12.04

<.0001

-

-

-

-
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Income a
Low

0.509209

0.36687368

1.39

0.1659

High

0.026453

0.37817921

0.07

0.9443

-

-

-

-

Middle class

Overall Health Status*
Excellent

28.062420

0.55912130

50.19

<.0001

Very good

25.481147

0.47509790

53.63

<.0001

Good

19.138884

0.43428593

44.07

<.0001

Fair

8.267454

0.44576231

18.55

<.0001

Poor

-

-

-

-

Comorbidities*
Asthma

-2.236821

0.44825096

-4.99

<.0001

Arthritis

-3.043042

0.34248529

-8.89

<.0001

Diabetes

1.694565

0.58220957

2.91

0.0038

High blood pressure

0.997117

0.45210909

2.21

0.0280

-

-

-

-

None

Number of comorbidities
2
≥3

0.779260

1.07477781

0.73

0.4688

-

-

-

-

Combination of antidepressants*
SSRI-MA**

2.479085

1.04549570

2.37

0.0182

SNRI-MA**

1.337592

1.46930357

0.91

0.3632

SSRI-SNRI

0.079626

2.37666638

0.03

0.9733

SSRI-TCA

0.112497

1.43652840

0.08

0.9376

Other combinations

0.403784

3.08942656

0.13

0.8961

None
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA** - Miscellaneous Agents
*Significant predictors
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between the
range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
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Table 8: Regression results for Mental Component Scores for combinations of
antidepressants

Parameter
Intercept*

Estimate

Standard Error

t Value

1.43485949

23.76

<.0001

34.089138

Pr > |t|

Age Groups*
18-44 years

-2.076411

0.38279452

-5.42

<.0001

> 65 years

3.147859

0.54721375

5.75

<.0001

45-65 years

-

-

-

-

-0.185170

0.35308193

-0.52

0.6002

-

-

-

-

Gender
Males
Females

Race
Blacks

1.008868

0.46058275

2.19

0.0290

Asians

-0.254178

1.25548987

-0.20

0.8397

Multiple Races

0.754341

1.01934443

0.74

0.4597

-

-

-

-

Whites

Marital Status*
Widowed

-0.741

0.63211

-1.17

0.2417

Divorced

-1.6109

0.44247

-3.64

0.0003

Separated

-1.7505

0.89523

-1.96

0.0512

Never married

-2.7223

0.43057

-6.32

<.0001

-

-

-

-

Married

Education
No education

-0.2248

1.55815

-0.14

0.8854

Elem/ Mid School

0.01862

0.65138

0.03

0.9772

High school

-0.0222

0.35052

-0.06

0.9496

5+ years college

0.60689

0.58198

1.04

0.2976

≤4 years college

-

-

-

-

Employment Status*
Employed
Unemployed

1.618264

0.41601700

3.89

0.0001

-

-

-

-
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Income a
Low

-0.181734

0.50670403

-0.36

0.7200

High

0.756142

0.51285046

1.47

0.1411

-

-

-

-

Middle class

Overall Health Status*
Excellent

18.376139

0.77668778

23.66

<.0001

Very good

14.833277

0.64242942

23.09

<.0001

Good

11.581959

0.59187438

19.57

<.0001

Fair

6.417728

0.59524026

10.78

<.0001

Poor

-

-

-

-

Comorbidities
Asthma

0.350122

0.52871868

0.66

0.5082

Arthritis

0.170229

0.42819455

0.40

0.6912

Diabetes

1.503815

0.76608830

1.96

0.0503

High blood pressure

0.404819

0.65851149

0.61

0.5391

-

-

-

-

None

Number of comorbidities
2
≥3

0.323815

1.13879645

0.28

0.7763

-

-

-

-

Combinations of antidepressants***
SSRI-MA**

-1.5584

1.35104

-1.15

0.2494

SNRI-MA**

-5.4855

3.90132

-1.41

0.1604

SSRI-SNRI

-2.0289

3.15032

-0.64

0.5199

SSRI-TCA

2.20433

2.9153

0.76

0.45

Other combinations

-1.6377

2.51062

-0.65

0.5145

None
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA** - Miscellaneous Agents
*Significant predictors, ***-Significant at α=0.1
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
No t – No therapy
MA* - Miscellaneous Agents
Both- Antidepressant and Psychotherapy both

Figure 3: Distribution of PHQ-2 scores across depression therapy classes

Table 9: Significant ANOVA results for PHQ-2 scores comparison across depression
therapy classes
Comparisons significant at the 0.05 level are indicated by ***.
Therapy Class

Difference
Between
Means

Simultaneous 95% Confidence
Limits

5: Psyc - 1: SSRI

0.35053

0.02424

0.67681

***

0: No t* - 1: SSRI

0.14484

0.02447

0.26521

***

1: SSRI - 5: Psyc

-0.35053

-0.67681

-0.02424

***

1: SSRI - 0: No t

-0.14484

-0.26521

-0.02447

***

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
No t* - No therapy
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Table 10: Regression results for PHQ-2 Scores for combinations of antidepressants

Parameter
Intercept*

Estimate

Standard Error

2.694124

t Value

0.48879317

5.51

Pr > |t|
<.0001

Age Groups*
18-44 years

0.217255

0.07258875

2.99

0.0029

> 65 years

-0.400896

0.11087437

-3.62

0.0003

45-65 years

-

-

-

-

0.087150

0.06934299

1.26

0.2095

-

-

-

-

Gender
Males
Females

Race*
Blacks

-0.183707

0.10973178

-1.67

0.0948

Asians

-0.151575

0.29001387

-0.52

0.6015

Multiple Races

-0.035496

0.24603147

-0.14

0.8854

-

-

-

-

Whites

Marital Status*
Widowed

0.02015

0.13274

0.15

0.8794

Divorced

0.23396

0.08047

2.91

0.0038

Separated

0.10532

0.21016

0.5

0.6165

Never married

0.15652

0.08804

1.78

0.0762

-

-

-

-

Married

Education
No education

-0.1324

0.27974

-0.47

0.6362

Elem/ Mid School

-0.1372

0.16398

-0.84

0.4034

High school

0.0792

0.07231

1.1

0.274

5+ years college

-0.1419

0.11152

-1.27

0.2039

≤4 years college

-

-

-

-

Employment Status*
Employed
Unemployed

-0.342392

0.08228428

-4.16

<.0001

-

-

-

-
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Income a
Low

0.160173

0.10910055

1.47

0.1428

High

-0.073283

0.08796945

-0.83

0.4053

-

-

-

-

Middle class

Overall Health Status*
Excellent

-2.870641

0.15753074

-18.22

<.0001

Very good

-2.540560

0.15289902

-16.62

<.0001

Good

-1.976290

0.14120859

-14.00

<.0001

Fair

-0.989290

0.14615247

-6.77

<.0001

Poor

-

-

-

-

Comorbidities
Asthma

0.023763

0.11088139

0.21

0.8304

Arthritis

0.033420

0.08681256

0.38

0.7005

Diabetes

-0.011586

0.14908447

-0.08

0.9381

High blood pressure

0.084496

0.10383440

0.81

0.4162

-

-

-

-

None

Number of comorbidities
2
≥3

0.305076

0.36284854

0.84

0.4009

-

-

-

-

Combinations of antidepressants
SSRI-MA**

-0.465199

0.36555129

-1.27

0.2039

SNRI-MA**

0.553461

0.49684260

1.11

0.2659

SSRI-SNRI

0.090573

0.36314474

0.25

0.8032

SSRI-TCA

-0.448151

0.80005073

-0.56

0.5757

Other combinations

-0.051863

0.20586987

-0.25

0.8012

-

-

-

-

None

Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants
MA** - Miscellaneous Agents
*Significant predictors
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
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Table 11: Multinomial regression results for depression frequency for combinations of
antidepressants
Predictor
Depression frequency (OR, Confidence Intervals)a
0: Not at all
1: Several Days
2: More Than Half
the Days
Age**
18-44 years
0.656**
0.836
1.112
(0.517, 0.833)
(0.653, 1.069)
(0.863, 1.434)
> 65 years
2.000**
1.361
1.201
(1.384, 2.889)
(0.963, 1.924)
(0.805, 1.793)
45-65 years
Reference
Reference
Reference
Males
Females
Blacks
Asians
Multiple races
Whites
Widowed
Divorced
Separated
Never Married
Married
No education
Elem/ Mid school
High school
5+ years college
≤ 4 years college
Employed
Unemployed
Low

Gender
0.866
0.886
(0.702, 1.069)
(0.724, 1.085)
Reference
Reference
Race **
1.394**
1.111
(1.029,1.889)
(0.842,1.467)
1.055
1.188
(0.557,2.001)
(0.661,2.138)
1.187
1.166
(0.580,2.432)
(0.632,2.151)
Reference
Reference
Marital Status**
0.682
0.786
(0.463,1.003)
(0.542,1.140)
0.622**
0.698**
(0.477,0.812)
(0.545,0.894)
0.531**
0.709
(0.318,0.887)
(0.438,1.150)
0.574**
0.655**
(0.422,0.782)
(0.493,0.871)
Reference
Reference
Education**
0.989
0.945
(0.303,3.222)
(0.308,2.897)
0.660
0.568**
(0.431,1.011)
(0.391,0.825)
0.726**
0.722**
(0.569,0.927)
(0.572,0.912)
1.127
0.989
(0.700,1.813)
(0.625,1.565)
Reference
Reference
Employment Status**
1.847**
1.599**
(1.413, 2.415)
(1.251, 2.045)
Reference
Reference
b
Income
0.752**
0.773
112

1.048
(0.828, 1.328)
Reference
1.572**
(1.167,2.119)
0.839
(0.357,1.972)
1.427
(0.746,2.731)
Reference
0.775
(0.503,1.193)
0.921
(0.701,1.208)
1.031
(0.599,1.775)
0.821
(0.601,1.124)
Reference
1.210
(0.348,4.209)
0.716
(0.462,1.108)
0.796
(0.615,1.030)
0.733
(0.407,1.320)
Reference
1.430**
(1.09, 1.895)
Reference
0.951

(0.566,0.999)
(0.595, 1.003)
(0.722, 1.251)
High
1.147
0.995
0.947
(0.786, 1.676)
(0.678, 1.461)
(0.608, 1.474)
Middle class
Reference
Reference
Reference
Overall Health Status
Excellent
119.049**
11.451**
1.613
(59.58, 237.87)
(5.772, 22.717)
(0.703, 3.702)
Very good
69.674**
12.815**
2.610**
(42.688, 113.720)
(8.477, 19.372)
(1.612, 4.228)
Good
23.542**
7.477**
1.966**
(15.703, 35.292)
(5.520, 10.129)
(1.402, 2.757)
Fair
5.512**
2.917**
1.521**
(3.724, 8.159)
(2.204, 3.860)
(1.116, 2.073)
Poor
Reference
Reference
Reference
Comorbidities
Asthma
1.111
1.053
0.877
(0.803, 1.538)
(0.774, 1.432)
(0.626, 1.230)
Arthritis
0.877
0.976
0.953
(0.664, 1.158)
(0.752, 1.266)
(0.726, 1.252)
Diabetes
1.330
1.355
1.042
(0.794, 2.228)
(0.814, 2.255)
(0.585, 1.856)
High blood pressure
1.082
0.848
1.158
(0.745, 1.572)
(0.583, 1.233)
(0.733, 1.829)
None
Reference
Reference
Reference
Number of Comorbidities
2
0.712
0.874
0.682
(0.310, 1.637)
(0.420, 1.819)
(0.312, 1.491)
≥3
Reference
Reference
Reference
Combinations of antidepressants**
SSRI-MA**
1.072
1.227
0.673
(0.351, 3.276)
(0.438, 3.435)
(0.193, 2.351)
SNRI-MA**
0.288
0.863
0.285
(0.040, 2.073)
(0.131, 5.687)
(0.021, 3.808)
SSRI-SNRI
0.542
0.723
N/Ac
(0.135, 2.177)
(0.192, 2.731)
SSRI-TCA
1.482
0.304
0.287
(0.174, 12.650)
(0.032, 2.885)
(0.028, 2.940)
Other combinations
0.951
0.329
0.052**
(0.258, 3.498)
(0.051,2.104)
(0.004,0.622)
None
Reference
Reference
Reference
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -Norepinephrine
Reuptake Inhibitor, TCA – Tricyclic antidepressants
*MA = Miscellaneous Agents
a
The reference class for depression frequency was 3: Nearly every day
** - Significant results
b
- Low defined as income <100% FPL (<$12,060), middle class defined as income between the
range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL
(>$48,240)
c
- N/A – Not applicable, since there were almost no patients in that group and the sample size for
that cell was < 5, the OR obtained for that particular group were absurd
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